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BACKGROUND: QT interval, measured through a standard ECG, captures 
the time it takes for the cardiac ventricles to depolarize and repolarize. 
JT interval is the component of the QT interval that reflects ventricular 
repolarization alone. Prolonged QT interval has been linked to higher risk 
of sudden cardiac arrest.
METHODS AND RESULTS: We performed an ExomeChip-wide analysis 
for both QT and JT intervals, including 209 449 variants, both common 
and rare, in 17 341 genes from the Illumina Infinium HumanExome 
BeadChip. We identified 10 loci that modulate QT and JT interval 
duration that have not been previously reported in the literature using 
single-variant statistical models in a meta-analysis of 95 626 individuals 
from 23 cohorts (comprised 83 884 European ancestry individuals, 
9610 blacks, 1382 Hispanics, and 750 Asians). This brings the total 
number of ventricular repolarization associated loci to 45. In addition, 
our approach of using coding variants has highlighted the role of 17 
specific genes for involvement in ventricular repolarization, 7 of which 
are in novel loci.
CONCLUSIONS: Our analyses show a role for myocyte internal structure 
and interconnections in modulating QT interval duration, adding to 
previous known roles of potassium, sodium, and calcium ion regulation, 
as well as autonomic control. We anticipate that these discoveries will 
open new paths to the goal of making novel remedies for the prevention 
of lethal ventricular arrhythmias and sudden cardiac arrest.
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Prolonged QT interval has been associated with in-creased risk of sudden cardiac arrest (SCA), a ma-jor cause of mortality, with between 180 000 and 
450 000 cases of SCA in the United States of America 
annually.1 Because the vast majority of SCA occurs in 
the absence of clinical features that would bring a vic-
tim to medical attention,2 identifying additional risk fac-
tors and dissecting the pathogenesis of disease are of 
high importance.
Heritability estimates of QT interval are between 
30% and 40%, indicating that genetic variants play a 
large role in modulating QT interval in the general pop-
ulation.3 Mendelian syndromes of QT interval (long- 
and short-QT syndrome), which lead to increased risk 
of cardiac arrhythmias and SCA, occur in ≈1 in 2000 
individuals and are caused by variants in ion chan-
nels or their interacting proteins.4 Previous candidate 
gene and genome-wide association studies (GWAS), 
largely screening common noncoding variants, have 
identified 35 loci containing variants that modestly 
influence QT interval, the largest of these studies, the 
QT Interval International GWAS Consortium (QT-IGC),5 
included a discovery population of 76 061 European 
ancestry individuals.
In this study, we conduct ExomeChip-wide analyses 
in population-based samples to interrogate the role of a 
largely unstudied class of variation on ventricular repo-
larization in the population—coding single nucleotide 
variants (SNVs). These variants fill in the gap between 
the extremely rare large-effect coding variants that 
result in the Mendelian long- and short-QT syndromes 
and the common small-effect largely noncoding varia-
tion identified through GWAS. The focus on exons and 
coding variants has an added benefit of directly impli-
cating genes. By contrast, noncoding variation typically 
implicates a region of the genome, often containing 
multiple genes, and therefore requiring extensive func-
tional experiments to implicate a specific gene. Further-
more, in this study, we examine both QT and JT interval 
to more comprehensively examine ventricular repolar-
ization. We have previously observed that variation in 
specific loci can influence ventricular depolarization and 
repolarization in a concordant fashion.5,6
We performed a meta-analysis of 23 cohorts includ-
ing 95 626 multiethnic individuals comprised 83 884 
European ancestry individuals, 9610 blacks, 1382 His-
panics, and 750 Asian individuals (Table I in the in the 
Data Supplement). Each individual was genotyped for 
191 740 coding SNVs in 17 341 genes using the Illu-
mina Infinium HumanExome BeadChip (ExomeChip), 
along with 17 709 noncoding SNVs of known impor-
tance from previous GWAS and variants tiling across 
the genome. These variants were chosen by evaluat-
ing ≈12 000 exome sequences for coding variants that 
appeared in at least 3 individuals.
METHODS
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing 
the results, subject to Data Use/Sharing Agreements adopted 
by individual participating cohorts. GWAS summary results 
will be available through the CHARGE Consortium Summary 
Results webpage available at dbGaP (phs000930).
This study was approved by local institutional review 
boards, and all participating subjects gave informed consent 
(detailed ethics statements in the Data Supplement).
SNV Association Tests and Meta-Analysis
Detailed methods are provided in the Data Supplement. 
Briefly, all cohorts excluded individuals with QRS intervals 
≥120 ms, heart rate <40 beats per minute or >120 beats per 
Clinical Perspective
Prolonged QT interval has been associated with 
increased risk of sudden cardiac arrest, a major 
cause of mortality, with between 180 000 and 
450  000 cases of sudden cardiac arrest in the 
United States of America annually. Because the 
vast majority of sudden cardiac arrest occurs in 
the absence of clinical features that would bring 
a victim to medical attention, identifying addi-
tional risk factors and dissecting the pathogen-
esis of disease are of high importance. In this 
study, we conduct ExomeChip-wide analyses in 
95 626 population-based multiethnic individu-
als to interrogate the role of a largely unstudied 
class of variation on ventricular repolarization in 
the population—coding single nucleotide vari-
ants. These variants fill in the gap between the 
extremely rare large-effect coding variants that 
result in the Mendelian long- and short-QT syn-
dromes and the common small-effect largely 
noncoding variation identified through genome-
wide association studies. The focus on exons and 
coding variants has an added benefit of directly 
implicating genes. Our approach of focusing on 
coding variants and both QT and JT intervals 
measures has identified 10 novel loci associated 
with ventricular repolarization and has implicated 
17 specific genes, 7 of which are in novel loci. 
Our analyses show a role for myocyte internal 
structure and interconnections in modulating QT 
interval duration, adding to previous known roles 
of potassium, sodium, and calcium ion regula-
tion, as well as autonomic control. We anticipate 
that these discoveries will open new paths to the 
goal of making novel remedies for the prevention 
of lethal ventricular arrhythmias and sudden car-
diac arrest.
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minute , left or right bundle branch block, atrial fibrillation on 
baseline ECG, Wolff–Parkinson–White syndrome, pacemaker, 
use of class I or class III blocking medication, or pregnant. 
Clinical characteristics summary statistics for each cohort are 
provided in Table I in the Data Supplement.
SNV effect size estimates are calculated via standard 
inverse variance–weighted meta-analysis of results provided 
by each cohort from a linear association model with QT/JT 
as the dependent variable, including covariates age, sex, RR 
interval (inverse heart rate), height, body mass index, and 
cohort-specific adjustments (principal components, clinic, 
family structure). Significance is similarly calculated by inverse 
variance–weighted meta-analysis; however, instead of raw 
QT/JT as the dependent variable in the linear regression, an 
inverse rank normal transformation is performed (details in 
the Data Supplement). These 2 models are used in tandem 
to avoid P value inflation from the analysis of the rare vari-
ants on the ExomeChip while maintaining the easy interpreta-
tion of effect sizes in milliseconds. The main analysis included 
all ethnic groups meta-analyzed together. SNVs with minor 
allele count <10 were excluded from the meta-analysis. SNVs 
were considered statistically significant if they exceeded the 
Bonferroni correction threshold of P<2×10−7.
Use of Functional Variants to Implicate 
Individual Genes Using Genome-Wide 
Significance
Genome-wide significance (GwiS) uses a greedy forward 
selection algorithm to identify independent genetic effects 
within a given gene/locus.7 A locus was defined by the SNV 
with the most significant association±1 megabase. GWiS was 
run on European-only summary statistics from 22 cohorts (QT, 
n=83 884; JT, n=80 330), with linkage disequilibrium (LD) esti-
mated from the merged ExomeChip and HapMap-imputed 
Atherosclerosis Risk in Communities (ARIC) European ancestry 
data set (n=9537; Data Supplement). An attempt to replace 
GWiS identified noncoding variants with equivalent coding 
variants (r2>0.8) did not yield any substitutions.
RESULTS
QT Interval ExomeChip Analysis 
Identifies 6 Novel Loci
Meta-analysis identified SNVs in 25 loci associated with 
QT interval at ExomeChip-wide significance (P<2×10−7; 
Figure I in the Data Supplement). Of these, 19 loci 
were previously associated with QT interval, and 6 loci 
were novel (Table 1). At 4 of these novel loci (PM20D1, 
SLC4A3, CASR, and NRAP), the top hit is a nonsynony-
mous variant. For the 2 novel loci where the index SNV 
is a noncoding variant, no genes in these loci harbored 
coding SNVs associated with QT interval. Analyses 
stratified by ethnicity found similar effect sizes between 
European ancestry individuals and blacks and same 
general direction of effects in the much smaller Hispan-
ics (n=1382) and Chinese (n=750) cohorts (Table II and 
Figure II in the Data Supplement).
Nineteen of the 25 loci associated with QT interval 
at ExomeChip-wide significance in our study had been 
associated with QT interval in prior European ancestry 
GWAS studies (Table 2, *P value). Table 2 detail the 35 
known QT loci identified from prior GWAS of Europe-
an ancestry individuals. Of the 14 previously identified 
loci for which the most significant SNV in our current 
study is a coding variant (Table 2, A), 3 loci reached 
ExomeChip-wide significance in our study (*P value). 
Of the 21 previously identified loci for which the most 
significant SNV in our study is a noncoding variant 
not in LD (r2>0.8) with a nearby coding variant, 16 
loci exceeded the significance threshold in our study 
(Table  2, B, *P value). For 5 of these 16 loci where 
the top signal was a noncoding SNV, they nonetheless 
harbored coding variants in ≥1 nearby genes that also 
reached ExomeChip-wide significance (Table II in the 
Data Supplement).
Table 1. Six Novel Loci Associated With QT Interval
Nearby 
Gene SNV Chr
Coded/ 
Noncoded  
Allele CAF
Effect in ms 
(SE) P Value Function
Gene(s) With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
PM20D1
rs1361754 1 G/A 0.511 0.47 (0.08) 1E-09 Nonsynonymous PM20D1
 PM20D1,*  
NUCKS1, RAB7L1,* 
SLC41A1
SLC4A3 rs55910611 2 A/G 0.006 −3.06 (0.61) 2E-07 Nonsynonymous SLC4A3   
CASR rs1801725 3 T/G 0.126 −0.58 (0.12) 4E-08 Nonsynonymous CASR  CSTA
ZNF37A rs4934956 10 T/C 0.497 0.58 (0.10) 2E-10 Intergenic    
NRAP rs3189030 10 A/G 0.299 −0.48 (0.09) 4E-08 Nonsynonymous NRAP NRAP CASP7*
GOSR2 rs17608766 17 C/T 0.123 0.72 (0.12) 3E-09 UTR3   RPRML
Significance was determined from analysis of inverse rank normal transformed residuals to avoid P value inflation from the analysis of rare variants. Effect 
size estimates in milliseconds (ms) are reported from untransformed analyses. n=95 626 number of samples. DEPICT9 genes pass FDR <5% cutoff. Expression 
quantitative trait loci (eQTL) genes are pulled from the Genotype-Tissue Expression portal10,11 using the representative SNV and GWiS independent SNVs. CAF 
indicates coded allele frequency; DEPICT, Data-driven Expression-Prioritized Integration for Complex Traits; FDR, false discovery rate; GwiS, genome-wide 
significance; SNV, single-nucleotide variants; and UTR3, three prime untranslated region.
*Gene if the eQTL is in the left ventricle.
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Table 2. Thirty-Five Loci Previously Associated With QT Interval
Nearby Gene SNV Chr
Coded/ 
Noncoded 
Allele CAF
Effect in 
ms (SE) P Value Function
QT-IGC 
Implicated 
Gene(s)
Gene(s) 
With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
A, Known QT loci with coding variant as top SNV
  RNF207 rs709209 1 G/A 0.379 1.23 (0.09) 1E-48* Nonsynonymous RNF207(c) RNF207 RNF207 GPR153
  SP3 rs1047640 2 C/T 0.120 0.60 (0.12) 3E-06 Nonsynonymous  SP3   
  TTN-
CCDC141
rs72648998 2 T/C 0.054 1.00 (0.18) 3E-09*
Nonsynonymous CCDC141(i), 
TTN(i)
TTN
 FKBP7, 
PRKRA
  SPATS2L
rs192861441 2 A/G 0.004 −2.22 (0.67) 3E-04 Nonsynonymous
SPATS2L(t), 
SGOL2(p)
   
  C3ORF75
rs2276853 3 G/A 0.411 −0.36 (0.08) 2E-05 Nonsynonymous
KLHL18(t), 
PTPN23(t), 
SCAP(t), SETD2(t), 
MYL3(i)
 
NBEAL2
NBEAL2, 
PTPN23, 
SCAP
  SMARCAD1 rs7439869 4 T/C 0.378 0.41 (0.08) 8E-07 Nonsynonymous  SMARCAD1   
  GMPR
rs1042391 6 T/A 0.551 −0.42 (0.09) 3E-06
Nonsynonymous GMPR(c), 
ATXN1(tp)
GMPR  GMPR
  KCNH2 rs1805123 7 G/T 0.214 −1.47 (0.10) 7E-51* Nonsynonymous KCNH2(p) KCNH2†  KCNH2
  LAPTM4B rs17831160 8 A/G 0.030 −0.64 (0.24) 3E-03 Nonsynonymous     
  AZIN1 rs143025416 8 A/G 0.001 4.90 (1.55) 2E-03 Nonsynonymous     
  GBF1
rs143226354 10 T/C 8.89E-05 14.18 (4.66) 4E-03
Splicing/ 
nonsynonymous
ACTR1A(i)
   
  ATP2A2
rs11068997 12 A/G 0.040 −0.94 (0.21) 4E-07 Nonsynonymous
VPS29(t),  
GPN3(t), 
ARPC3(t), 
C12ORF24(t), 
ATP2A2(pi)
GIT2, TCTN1
ATP2A2, 
PPTC7
 
  USP50-
TRPM7 rs8042919 15 A/G 0.097 −0.57 (0.14) 4E-05 Nonsynonymous
   SPPL2A, 
AP4E1, 
USP50
  CREBBP rs143903106 16 T/G 0.001 4.10 (1.46) 5E-03 Nonsynonymous TRAP1(i)    
B, Known QT loci with noncoding variant as top SNV
  TCEA3
rs1077514 1 G/A 0.179 −0.58 (0.11) 4E-08* Intronic
TCEA3(t)   TCEA3,‡ 
ASAP3
  NOS1AP rs12143842 1 T/C 0.240 3.18 (0.10) 3E-255* Intergenic     
  ATP1B1
rs10919071 1 G/A 0.115 −1.37 (0.13) 3E-30* Intronic
ATP1B1(ti), 
NME7(t)
  NME7
  SLC8A1 rs2540226 2 T/G 0.482 0.24 (0.08) 2E-03 Intergenic SLC8A1(p)   THUMPD2
  SCN5A-
SCN10A
rs12053903 3 C/T 0.379 −0.88 (0.09) 1E-26* Intronic SCN5A(p) SCN10A SCN5A
SNORA6, 
SCN5A§
  SLC4A4 rs7689609 4 C/T 0.212 0.64 (0.12) 4E-08* Intronic     
  GFRA3
rs4835768 5 G/A 0.485 0.34 (0.08) 7E-05 Intergenic
FAM13B(t), 
ETF1(p)
 MYOT, 
FAM13B
 
  SLC35F1-PLN rs11153730 6 C/T 0.467 1.41 (0.08) 5E-74* Intergenic PLN(i)  PLN SSXP10
  CAV1
rs3807989 7 A/G 0.429 0.54 (0.08) 4E-12* Intronic
CAV1(pi), 
CAV2(pi)
  AC002066.1
  NCOA2 rs2926707 8 G/T 0.348 0.31 (0.09) 3E-04 Intronic     
  KCNQ1
rs2074238 11 T/C 0.074 −3.58 (0.16) 8E-130* Intronic
C11ORF21(t), 
PHEMX(t), 
TSPAN32(t), 
KCNQ1(p)
KCNQ1 KCNQ1
 
  FEN1-FADS2
rs1535 11 G/A 0.325 −0.48 (0.09) 8E-10* Intronic
FADS1(t), 
FADS2(t), 
FADS3(t)
  FAD2,‡ 
FADS1, 
TMEM258
  KLF12 rs1886512 13 A/T 0.381 0.57 (0.09) 2E-10* Intronic KLF12(t)   KLF12‡
  ANKRD9 rs11704 14 C/G 0.291 0.35 (0.09) 7E-05 UTR3 ANKRD9(t)  ANKRD9 ZNF839
(Continued )
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JT Interval Association Identifies  
4 Novel Loci
Although ventricular depolarization and repolarization 
are often coregulated, this is not universally true. There-
fore, to more specifically examine ventricular repolariza-
tion, we also investigated genetic associations with JT 
interval, defined mathematically by subtracting the QRS 
interval (ventricular depolarization and conduction) 
from the QT interval, which primarily reflects ventricular 
repolarization.8 Among the 15 590 ARIC participants, 
the correlations (r2) among the intervals were 0.84 for 
QT and JT; 0.02 for QRS and JT; and 0.08 for QT and 
QRS. We analyzed JT interval as described above for 
QT interval while adding QRS interval as an additional 
covariate to further remove the effect of ventricular 
depolarization on the analysis. Thirty coding variants in 
14 loci were associated with JT interval (Table III and 
Figure III in the Data Supplement). Four of these 14 loci 
were not identified as QT interval loci (Table 3). Three 
of these 4 novel repolarization loci had index SNVs that 
were coding variants: SENP2, SLC12A7, and NACA. The 
SNV rs9470361 (near CDKN1A) has previously been 
associated with QRS interval with an effect size esti-
mate in the opposite direction (Table 3). Indeed, for 3 
of these loci (SENP2, CDKN1A, and NACA), where an 
association was found with JT but not with QT interval, 
the index SNVs were significantly associated with QRS 
duration but with effect estimates in the opposite direc-
tion (Table 3). Hence, at these loci, variants that prolong 
the QRS interval (depolarization) shorten the JT inter-
val (repolarization). Analyses run stratified by ethnicity 
found similar effect sizes between European ancestry 
individuals and blacks (Table III in the Data Supplement).
Use of Coding Variants to Implicate 
Specific Genes
Leveraging information from nominally significant cod-
ing SNVs, we sought to implicate causative genes in 
each locus by demonstrating that putatively functional 
coding variants are associated with ventricular repo-
larization independently of noncoding SNVs. We have 
previously5 shown that several QT loci contain multiple 
independent genetic effects, including some loci har-
boring multiple significant coding variants (Tables II and 
III in the Data Supplement). Thus, even if not the top hit 
at a locus, putative functional SNVs can still implicate a 
specific gene at a locus. We used the GWiS7 algorithm to 
determine the number of independent effects in all 45 
ventricular repolarization associated loci from Tables 1 
through 3 and to identify the SNV that best represents 
each independent effect in European ancestry indi-
viduals (n=83 884; Table IV in the Data Supplement). 
The SCN5A-SCN10A locus is a particularly illustrative 
example of the use of this approach. Although cod-
ing variants in DLEC1, SCN5A, and SCN10A are each 
ExomeChip-wide significant, after using GWiS, the 
  LITAF rs8049607 16 T/C 0.503 1.05 (0.08) 8E-44* Intergenic LITAF(t)   LITAF‡
 MKL2 rs30208 16 T/C 0.501 0.45 (0.08) 2E-09* Intergenic     
  CNOT1
rs7188697 16 G/A 0.247 −1.57 (0.10) 4E-63* Intronic
NDRG4(t), 
CNOT1(t), GOT2(i)
  SETD6, 
NDRG4
  LIG3
rs2074518 17 A/G 0.428 −0.79 (0.08) 2E-21* Intronic
LIG3(t), CCT6B(t), 
UNC45B(i)
  LIG3,‡ 
CCT6B, 
RFFL,‡ RP5-
837J1.2
  PRKCA rs9912468 17 G/C 0.417 −0.68 (0.08) 2E-15* Intronic PRKCA(t)   PRKCA‡
  KCNJ2 rs17779747 17 T/G 0.304 −1.08 (0.09) 3E-37* Intergenic     
  KCNE1 rs727957 21 T/G 0.168 0.48 (0.11) 3E-05 Intronic KCNE1(cp)    
A section lists the 14 (of 35) previously identified loci (QT-IGC study of European ancestry individuals5) for which the most significant SNV in our current study is a coding 
variant. Because of the design of the Exome Chip with a focus on coding variants, only select intronic or intergenic SNVs were interrogated, and therefore not all QT-IGC 
SNVs were examined. B section lists the 21 previously identified loci for which the most significant SNV in our study is a noncoding variant not in LD (r2>0.8) with a nearby 
coding variant. Significance was determined from analysis of inverse rank normal transformed residuals to avoid P value inflation from the analysis of rare variants. Effect size 
estimates in milliseconds (ms) are reported from untransformed analyses. n=95 626 number of samples. Within the QT-IGC Implicated Gene(s) column, evidence for the gene 
is c, coding variant; t, eQTL transcript; p, in silico protein-protein interactor; i, immunoprecipitation interactor. DEPICT9 genes pass FDR<5% cutoff. Expression quantitative trait 
loci (eQTL) genes are pulled from the Genotype-Tissue Expression portal10,11 using the representative SNV and GWiS independent SNVs. CAF indicates coded allele frequency; 
DEPICT, Data-driven Expression-Prioritized Integration for Complex Traits; FDR, false discovery rate; GwiS, genome-wide significance; QT-IGC, QT Interval International GWAS 
Consortium, and SNV, single nucleotide variants.
*P value if significantly associated after Bonferroni correction, P<2×10−7.
‡Gene if the eQTL is in the left ventricle.
§GWiS independent SNV rs9851724 used to identify eQTL.
†Conditional analyses in ARIC contradict this result, see text for details.
Table 2. Continued
Nearby Gene SNV Chr
Coded/ 
Noncoded 
Allele CAF
Effect in 
ms (SE) P Value Function
QT-IGC 
Implicated 
Gene(s)
Gene(s) 
With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
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signal coming from the coding variants in DLEC1 and 
SCN5A is explained by noncoding variants, and only 
the SCN10A coding variant signal remains (Table V in 
the Data Supplement). In the Gene(s) with independent 
coding variation column in Tables 1 through 3, we list 
the 17 genes in 16 loci that have an independent effect 
represented by a coding variant.
For the loci listed in Table 2 B, such as the SCN5A-
SCN10A locus, where intronic and intergenic variants 
were included in the analyses, the independent associa-
tions in coding SNVs identified by GWiS are independent 
of the noncoding variants in the region. This analysis 
implicates 2 genes for involvement in cardiac repolariza-
tion among those of European descent: SCN10A and 
KCNQ1. For the novel loci in Table  1 where a coding 
SNV is the most significant association in our study, it is 
unlikely that noncoding variants of importance are pres-
ent in those loci because the loci were not found during 
the QT-IGC efforts, a study of similar sample size.
In contrast, for the 14 previously identified QT loci 
where the top SNV in our study was a coding variant 
(Table 2, A), the GWiS findings are less conclusive because 
intronic and intergenic SNVs were largely not examined 
in these regions. Therefore, to determine whether the 
associated coding variants are independently associated 
with QT interval and hence implicate a causal gene, or 
alternatively, are associated simply because of LD with a 
more strongly associated noncoding variant not geno-
typed with the ExomeChip, we performed additional 
analyses in a subset of the data set, ARIC, that includes 
both the QT-IGC top SNV, as well as the top SNV, from 
the current study. We performed conditional analyses at 
the 7 loci in Table 2, A where significant associations were 
identified by GWiS (the remaining 7 loci did not have any 
SNVs identified as significant by GWiS after accounting 
for multiple testing), by including both the QT-IGC and 
ExomeChip variants in the same regression model in the 
ARIC Europeans data set (n=9537; Table VI in the Data 
Supplement). Conditional analyses demonstrate that the 
coding variant in SP3 is independent of the top noncod-
ing SNV at this locus discovered from QT-IGC, implicat-
ing this gene in QT interval modulation. For GMPR, the 
coding variant is in almost perfect linkage disequilibrium 
with the noncoding QT-IGC variant (r2=0.99 in ARIC), 
suggesting that the coding variant may be the causal 
variant explaining the QT-IGC signal. For a third locus, 
RNF207, although conditional analysis suggested that 
the QT-IGC SNV accounts for the association at this locus, 
both the top QT-IGC SNV as well as the top SNV from 
this study are coding variants in high LD, thus implicat-
ing the RNF207 gene in myocardial repolarization. For the 
remaining 4 loci, 1 coding variant is associated because of 
the stronger noncoding QT-IGC signal (KCNH2); 2 were 
not properly tested because of no effect in ARIC of the 
ExomeChip variant (ATP2A2) or the QT-IGC variant (TTN), 
although there was low LD (r2<0.04) between the coding 
and noncoding variants, suggesting independence; and 
1 was unclear (SMARCAD1), as putting both SNVs in the 
model significantly altered the β estimates for both SNVs.
In Silico Analyses to Implicate Causal Genes
To further decode the role these loci might play in regu-
lating ventricular repolarization, Data-driven Expression-
Prioritized Integration for Complex Traits9 was used to 
investigate whether identified loci contain genes from 
functional annotated gene sets/pathways. Included in 
Tables  1 through 3 in the DEPICT Implicated Gene(s) 
column is a list of genes with a false discovery rate 
<5%. Furthermore, we looked up each of the Tables 1 
through 3 SNVs in the Genotype-Tissue Expression Por-
tal to identify single-tissue expression quantitative trait 
loci10,11 (left ventricle expression quantitative trait loci, 
represented by footnote symbols in tables). Findings for 
Table 3. Four Novel Loci Associated With JT Interval
Nearby 
Gene SNV Chr
Coded/ 
Noncoded 
Allele CAF
JT Effect  
in ms (SE)
JT P 
Value
QRS Effect  
in ms (SE)
QRS P 
Value Function
Gene(s) With 
Independent 
Coding 
Variation
DEPICT 
Implicated 
Gene(s) eQTL
SENP2 rs6762208 3 A/C 0.358 0.44 (0.08) 2E-07* −0.31 (0.05) 3.45E-12* Nonsynonymous SENP2   
SLC12A7
rs737154 5 C/T 0.500 −0.40 (0.08) 2E-07* 0.07 (0.04) 8.84E-02
Splicing/ 
synonymous
SLC12A7  NKD2
CDKN1A rs9470361 6 A/G 0.249 −0.76 (0.09) 2E-15* 0.84 (0.05) 1.21E-63* Intergenic    
NACA rs2926743 12 A/G 0.252 0.53 (0.09) 6E-08* −0.32 (0.05) 9.40E-11* Nonsynonymous NACA RBMS2  
Significance was determined from analysis of inverse rank normal transformed residuals to avoid P value inflation from the analysis of rare variants. Effect 
size estimates in milliseconds (ms) are reported from untransformed analyses. QRS interval association summary data for these 4 variants were contributed by 
our coauthors Drs Prins, Jamshidi, and Arking from ExomeChip analyses they are running as a part of the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium Electrocardiogram (EKG) working group. n=95 626 samples for JT interval association and n=85 593 samples for QRS interval 
association. DEPICT9 genes pass FDR<5% cutoff. Expression quantitative trait loci (eQTL) genes are pulled from the Genotype-Tissue Expression portal10,11 using the 
representative SNV and GWiS independent SNVs. CAF indicates coded allele frequency; DEPICT, Data-driven Expression-Prioritized Integration for Complex Traits; 
FDR, false discovery rate; GwiS, genome-wide significance; and SNV, single nucleotide variants.
*P value if significantly associated after Bonferroni correction, P<2×10−7.
†Gene if the eQTL is in the left ventricle.
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Data-driven Expression-Prioritized Integration for Com-
plex Traits and expression quantitative trait loci analy-
ses are largely consistent with those genes identified 
because of harboring significant coding variants and 
help clarify the causative gene.
DISCUSSION
Our approach of focusing on coding variants and both 
QT and JT intervals has identified 10 novel loci associ-
ated with ventricular repolarization and has implicated 
17 specific genes, 7 of which are in novel loci. Previous 
studies have implicated roles for potassium ion regu-
lation, sodium ion regulation, calcium ion regulation, 
and autonomic control of QT interval,12 and our results 
provide support for each of these pathways. SLC12A7 
(KCC4), which is highly expressed in the left ventri-
cle,10,11 is a potassium chloride cotransporter involved in 
potassium efflux.13 CASR is a G protein–coupled recep-
tor that maintains circulating calcium ion homeostasis 
via parathyroid hormone secretion in the parathyroid 
and kidney tubule ion handling.14
In addition to previously implicated pathways, our 
analyses highlight a role for genes involved in generating 
the physical force of contraction inside of cardiomyocytes 
and for conducting electric signal between cardiomyo-
cytes across the heart. Pathway enrichment analyses 
using Data-driven Expression-Prioritized Integration for 
Complex Traits (detailed methods in the Data Supple-
ment) identified the GO category GO:0005916, which 
comprised the genes that code for fascia adherens, the 
structure that links myofibrils between cardiomyocytes, 
and contains N-cadherin. NRAP, found to have a signifi-
cant independent coding variant, likely anchors terminal 
actin filaments of myofibrils to other protein complexes 
beneath the sarcolemma15,16 and is expressed exclusively 
in skeletal muscle and heart.10,11 skNAC (skeletal NACA) 
knockout mice, a muscle-specific isoform of NACA, 
which was found to have a significant independent cod-
ing variant, die between embryonic days 10.5 and 12.5 
because of cardiac defects, showing interventricular sep-
tal defects and a thin myocardial wall.17 With these 3 
points of evidence combined with the previously known 
locus and GWiS-implicated gene, TTN, a clear class of 
genes emerge that influence ventricular repolarization 
through their effect on myocyte structure.
It is important to note that the intercalated disc, 
which is the interface between cardiomyocytes, con-
tains fascia adherens, desmosomes, and gap junctions, 
the last of which is known to play a role in ion-medi-
ated relaying of action potentials between cardiomyo-
cytes and, in combination with the gene NOS1AP, has 
been implicated as regulating QT interval.18 In contrast, 
we implicate a nonion-dependent structural/mechani-
cal interconnect between cardiomyocytes mediated by 
the fascia adherens.
By looking specifically at ventricular repolarization (JT 
interval) without the influence of depolarization (QRS 
interval), we detected additional loci related to ventric-
ular repolarization while teasing apart the differential 
regulation of the various phases of ventricular conduc-
tion. Our current results are consistent with our prior 
findings that variation in some loci influence ventricular 
depolarization and repolarization in a concordant fash-
ion, others influence depolarization and repolarization 
in a discordant fashion, and still other loci are associat-
ed with one phenotype and not the other.5,6 Although 
ventricular depolarization and repolarization are often 
coregulated, the difference in genetic effect indicates 
this is not universally true. Several limitations should be 
noted. First, we did not have an additional sample to 
perform replication studies although results were con-
sistent across the diverse cohorts included in our study 
(Figures IV–XIII in the Data Supplement). Second, cor-
relation of effect sizes was weak between the European 
ancestry and Hispanic and Asian populations, limiting 
extrapolation of findings to these populations.
In summary, we have identified 10 loci newly asso-
ciated with ventricular repolarization. This brings the 
total number of ventricular repolarization–associated 
loci to 45. In addition, we have directly implicated 17 
specific genes contained in these loci as likely affecting 
ventricular repolarization and outlined a class of genes 
that mechanically control QT interval. These new dis-
coveries will likely allow for the development of novel 
vectors for the prevention of lethal ventricular arrhyth-
mias and SCA.
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Supplemental Methods 
Genotyping and Quality Control 
Genotyping and quality control followed ExomeChip best practices put out by the CHARGE Consortium1. 
 
SNV Association Tests and Meta-Analysis 
SNV effect size estimates are calculated via standard inverse variance weighted (IVW) meta-analysis of results 
provided by each cohort from a linear association model with QT/JT as the dependent variable, including 
covariates age, sex, RR interval, height, body mass index (BMI), and cohort specific adjustments (principal 
components, clinic, family structure). Significance (P value) is determined by first inverse rank normal 
transforming residuals from a linear model with QT/JT as the outcome using covariates: Age, Sex, RR interval, 
Height, and BMI, then running a standard IVW meta-analysis on a linear association model with the 
transformed residuals as the outcome using cohort specific adjustments as covariates. These two models are 
used in tandem to avoid P value inflation from the analysis of the rare variants on the ExomeChip while 
maintaining the easy interpretation of effect sizes in milliseconds. 
Representative SNVs have the lowest p-value in each locus. QT loci are considered discovered if 
passing a Bonferroni correction, P<0.05 / 209,449 SNVs (2E-07). JT loci are considered discovered if passing a 
Bonferroni correction, P< 0.05 / 208,917 SNVs (2E-07). The difference in the number of SNVs is due to the 
fact not all cohorts that contributed data to the QT analysis contributed data to the JT analysis. Cohorts 
contribute slightly different number of SNVs due to individual QC efforts. Variants with minor allele counts 
less than 10 were excluded from the meta-analysis.  
 
LD Calculations and Conditional Analyses 
LD calculations were performed in the merged ExomeChip and HapMap-imputed ARIC European-ancestry 
dataset with 9,537 samples. Conditional analyses were run only if the QT-IGC variant had a nominal 
association in ARIC (P<0.05) to ensure the effect size estimate was stable. 
 
Utilization of Functional Variants to Implicate Individual Genes using GWiS 
Gene-Wide Significance (GWiS) uses a greedy forward selection algorithm to identify independent genetic 
effects within a given gene/locus2. We defined each locus as the most significant SNV ±1 MB and ran on 
European-only summary statistics from 22 cohorts for a sample size of 83,884 in QT analyses and 80,330 in JT 
analyses. GWiS finds the number of independent effects in each locus along with a SNV that best represents 
each independent effect. This is important because even coding variants may be significant in the analysis due 
to LD with a causal non-coding variant. The LD information needed for the GWiS analysis was estimated in the 
ARIC Europeans dataset as described above. To ensure accurate estimates of LD, the GWiS analysis was 
limited to European-only because ARIC has a large number of European-ancestry individuals. An attempt to 
replace GWiS identified non-coding variants with equivalent coding variants (r2>0.8) did not yield any 
substitutions. 
 
SKAT Gene-based Tests 
SKAT tests were performed using the R package “seqMeta” with rare variants (MAF ≤ 0.01) from each gene. 
Variants were filtered to those that alter protein coding: frame-shift, nonsynonymous, stop-gain, stop-loss, or 
splicing1. In a second analysis, the nonsynonymous variants were further filtered to those predicted to be 
damaging by at least two of the following prediction algorithms: Polyphen2, LRT, SIFT, Mutation Taster1. 
Genes with only a single variant were excluded. Bonferroni corrected ExomeChip-wide significance is P<0.05 
divided by the number of genes tested in either of the variant filters: 29,368 for QT and 29,366 for JT. 
 
Pathway Enrichment  
To further decode the role whether QT/JT-associated loci might play in regulating ventricular repolarization, 
Data-driven Expression-Prioritized Integration for Complex Traits (DEPICT)3 was used to investigate if 
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identified loci contain genes from functional annotated gene sets/pathways. The 45 SNVs from Tables 1, 2, and 
3 were used to seed the algorithm, however, only 38 SNVs were able to be matched to DEPICT’s internal 
database used by the algorithm (Date Supplement Table VII). Included in Tables 1, 2, and 3 in the “DEPICT 
Implicated Gene(s)” column is a list of genes with a false discovery rate (FDR) < 5%. Three gene sets passed 
the FDR cutoff of 5%: C1QA subnetwork (ENSG00000173372; p=1.97E-6), fascia adherens (GO:0005916; 
p=8.28E-6), and ACOT13 subnetwork (ENSG00000112304; p=9.02E-6). Three tissues also passed the FDR 
cutoff of 5%: Heart Ventricles (A07.541.560; p=9.56E-4), Heart (A07.541; p=9.74E-4), and Atrial Appendage 
(A07.541.358.100; p=0.003). 
 
GTEx eQTL Lookup 
We looked up each of the Tables 1, 2, and 3 representative SNVs and GWiS independent SNVs (60 SNVs) in 
the GTEx Portal to identify single-tissue expression quantitative trait loci (eQTL)4,5. All eQTLs passed 
FDR<5%. The results are presented in Tables 1, 2, and 3’s “eQTL” column (left ventricle association noted in 
bold). Genes were excluded if the SNV was towards the bottom of an LD significance peak indicating the 
association is due to low-level LD with a stronger eQTL not associated with QT/JT interval: ATP1B1, 
ANKRD9, BAZ2A from the NACA locus. Interestingly, rs1361754 was found to be both an ExomeChip-wide 
significant coding variant in PM20D1 and an eQTL for the same gene in left ventricle. Furthermore, for loci 
where there were no independent coding SNV associations to implicate a causal gene, eQTL analysis from left 
ventricular tissue, arguably the most relevant tissue to the phenotype of cardiac repolarization, identifies 7 
additional genes potentially involved in myocardial repolarization (bolded genes in Table 2B). 
 
 
  
5 
 
Cohort Specific Methods 
AGES 
In anticipation of the sequencing of the human genome and description of the human proteome, the Age, 
Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik)6 was initiated in 2002. AGES-Reykjavik 
was designed to examine risk factors, including genetic susceptibility and gene/environment interaction, in 
relation to disease and disability in old age. The study is multidisciplinary, providing detailed phenotypes 
related to the cardiovascular, neurocognitive (including sensory), and musculoskeletal systems, and to body 
composition and metabolic regulation. Relevant quantitative traits, subclinical indicators of disease, and 
medical diagnoses are identified by using biomarkers, imaging, and other physiologic indicators. The AGES-
Reykjavik sample is drawn from an established population-based cohort, the Reykjavik Study. This cohort of 
men and women born between 1907 and 1935 has been followed in Iceland since 1967 by the Icelandic Heart 
Association. The AGES-Reykjavik cohort, with cardiovascular risk factor assessments earlier in life and 
detailed late-life phenotypes of quantitative traits, will create a comprehensive study of aging nested in a 
relatively genetically homogeneous older population. This approach should facilitate identification of genetic 
factors that contribute to healthy aging as well as the chronic conditions common in old age. 
 
ARIC 
The Atherosclerosis Risk in Communities study7 (https://www2.cscc.unc.edu/aric/) includes 15,792 men and 
women from four communities in the United States (Jackson, Mississippi; Forsyth County, North Carolina; 
Washington County, Maryland; suburbs of Minneapolis, Minnesota) enrolled in 1987–1989 and prospectively 
followed. ECGs were recorded at baseline using MAC PC ECG machines (Marquette Electronics) and 
processed initially by the Dalhousie ECG program in a central laboratory at the EPICORE Center (University of 
Alberta). Processing was later repeated for the present study using the GE Marquette 12-SL program (2001 
version) at the EPICARE Center (Wake Forest University). All ECGs were visually inspected for technical 
errors and inadequate quality. 
 
BRIGHT 
The BRIGHT study8 includes 2000 unrelated white European hypertensive individuals. Twelve-lead ECG 
recordings (Siemens-Sicard 440; http://www.brightstudy.ac.uk/info/sop04.html) producing automated 
measurements of the JT and QT interval were available for all subjects. All data were subsequently transferred 
from each recruitment centre by electronic modem to electrophysiologists from the West of Scotland Primary 
Prevention Study (Professor Peter MacFarlane) for central reporting. 
 
CAMP 
The MGH Cardiology and Metabolic Patient (CAMP MGH) cohort comprises 3857 subjects recruited between 
2008 and 2012. Two thirds of the subjects were drawn from patients who had appointments with a physician in 
the MGH Heart Center, whereas one third were recruited independent of any hospital visit. All subjects had 
plasma and serum samples collected, as well as blood for genomic DNA. ECG was performed on subjects who 
did not have a tracing within the past 6 months. 
 
CHS 
The Cardiovascular Health Study (CHS) is a population-based cohort study of risk factors for coronary heart 
disease and stroke in adults ≥65 years conducted across four field centers9. The original predominantly 
European ancestry cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare 
eligibility lists; subsequently, an additional predominantly African-American cohort of 687 persons were 
enrolled for a total sample of 5,888. CHS was approved by institutional review committees at each field center 
and individuals in the present analysis had available DNA and gave informed consent including consent to use 
of genetic information for the study of cardiovascular disease. 
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ERF 
The Erasmus Rucphen Family study10 is comprised of a family-based cohort embedded in the Genetic Research 
in Isolated Populations (GRIP) program in the southwest of the Netherlands. The aim of this program is to 
identify genetic risk factors for the development of complex disorders. In ERF, twenty-two families that had a 
large number of children baptized in the community church between 1850 and 1900 were identified with the 
help of detailed genealogical records. All living descendants of these couples, and their spouses, were invited to 
take part in the study. Comprehensive interviews, questionnaires, and examinations were completed at a 
research center in the area; approximately 3,200 individuals participated. Examinations included 12 lead ECG 
measurements. Electrocardiograms were recorded on ACTA electrocardiographs (ESAOTE, Florence, Italy) 
and digital measurements of the QT and JT intervals were made using the Modular ECG Analysis System 
(MEANS). Data collection started in June 2002 and was completed in February 2005. In the current analyses, 
965 participants for whom complete phenotypic, genotypic and genealogical information was available were 
studied. 
 
FHS 
The objective of the Framingham Heart Study was to identify the common factors or characteristics that 
contribute to CVD by following its development over a long period of time in a large group of participants who 
had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The researchers recruited 
5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began 
the first round of extensive physical examinations and lifestyle interviews that they would later analyze for 
common patterns related to CVD development. Since 1948, the subjects have continued to return to the study 
every two years for a detailed medical history, physical examination, and laboratory tests, and in 1971, the 
Study enrolled a second generation - 5,124 of the original participants' adult children and their spouses - to 
participate in similar examinations. In 1994, the need to establish a new study reflecting a more diverse 
community of Framingham was recognized, and the first Omni cohort of the Framingham Heart Study was 
enrolled. In April 2002 the Study entered a new phase, the enrollment of a third generation of participants, the 
grandchildren of the Original Cohort. In 2003, a second group of Omni participants was enrolled. 
 
Generation Scotland 
The Generation Scotland: Scottish Family Health Study (GS:SFHS)11 is a collaboration between the Scottish 
Universities and the NHS, funded by the Chief Scientist Office of the Scottish Government. GS:SFHS is a 
family-based genetic epidemiology cohort with DNA, other biological samples (serum, urine and cryopreserved 
whole blood) and socio-demographic and clinical data from ~24,000 volunteers, aged 18-98 years, in ~7,000 
family groups. Participants were recruited across Scotland, with some family members from further afield, from 
2006 - 2011. Most (87%) participants were born in Scotland and 96% in the UK or Ireland. GS:SFHS operates 
under appropriate ethical approvals, and all participants gave written informed consent. 
 
GOCHA 
The Genetics of Cerebral Hemorrhage on Anticoagulation (GOCHA) study12 is a multicenter study comprised 
of patients age >55 years presenting to participating hospitals with primary ICH. Controls were enrolled from 
ambulatory clinics in the same centers from which cases were recruited. 
 
GRAPHIC 
The GRAPHIC Study13 comprises 2024 individuals from 520 nuclear families recruited from the general 
population in Leicestershire, UK between 2003-2005 for the purpose of investigating the genetic determinants 
of blood pressure and related cardiovascular traits. Families were included if both parents aged 40-60 years and 
two offspring ≥18 years wished to participate. A detailed medical history was obtained from study subjects by 
standardized questionnaires and clinical examination was performed by research nurses following standard 
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procedures. Measurements obtained included height, weight, waist-hip ratio, clinic and ambulatory blood 
pressure and a 12-lead ECG. 
 
Inter99 
The Inter99 study14 carried out in 1999-2001 included invitation of 12934 persons aged 30-60 years drawn from 
an age- and sex-stratified random sample of the population. The baseline participation rate was 52.5%, and the 
study included 6784 persons. The Inter99 study was a population-based randomized controlled trial 
(CT00289237, ClinicalTrials.gov) and investigated the effects of lifestyle intervention on CVD. Here 5827 
participants with information on lipids and exome chip were analysed. ECG information was obtained from the 
MUSE Cardiology Information System (GE Healthcare, Wauwatosa, Wisconsin) analysed by Marquette 12SL 
algorithm version 21. 
 
JHS 
The Jackson Heart Study15 (https://www.jacksonheartstudy.org/) includes 5,306 African-American men and 
women from the three counties, Hinds, Madison, and Rankin, that comprise the Jackson, MS metropolitan area. 
Participants were enrolled in 2000-2004 and have been followed prospectively. A supine 12-lead digital 
electrocardiogram (ECG) was recorded with the Marquette MAC/PC digital ECG recorder (Marquette 
Electronics, Milwaukee, Wis), and with electrode placement that duplicates that of the ARIC study. The ECGs 
are analyzed in accordance with the Minnesota Code Classification system, via an extensively validated 
computer algorithm that was developed specifically for epidemiologic studies. In-hospital surveillance ECGs 
are read visually according to the Minnesota Code Classification system. 
 
KORA 
KORA (Kooperative Gesundheitsforschung in der Region Augsburg)16,17 is a series of independent population-
based epidemiological surveys and follow-up studies of participants living in the city of Augsburg, Southern 
Germany, or its two adjacent counties. All participants are residents of Germany and have been sampled in 
strata of age and sex from the local registries. In the baseline survey used in this study, KORA S4, 4,261 
subjects have been examined. 3,080 subjects participated in a 7-year follow-up examination of S4 in 2006-2008. 
Illumina HumanExome BeadChip was measured in KORA F4 participants. 
 
CROATIA-Korcula 
The CROATIA-Korcula18 study sampled Croatians from the Adriatic island of Korcula, between the ages of 18 
and 88. The fieldwork was performed in 2007 in the eastern part of the island, targeting healthy volunteers from 
the town of Korčula and the villages of Lumbarda, Žrnovo and Račišće. 
 
Lifelines 
LifeLines19 is a multi-disciplinary prospective population-based cohort study examining in a unique three-
generation design the health and health-related behaviours of 165,000 persons living in the North East region of 
The Netherlands. It employs a broad range of investigative procedures in assessing the biomedical, socio-
demographic, behavioral, physical and psychological factors which contribute to the health and disease of the 
general population, with a special focus on multimorbidity and complex genetics. Details of the protocol have 
been described elsewhere (https://www.lifelines.nl/lifelines-research/news). Standard 12-lead 
electrocardiograms were recorded with CardioPerfect equipment (Cardio Control; currently Welch Allyn, Delft, 
The Netherlands) and digital measurements of the QT intervals were extracted. 
 
MESA 
The Multi-Ethnic Study of Atherosclerosis (MESA)1,20 is a study of the characteristics of subclinical 
cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and 
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the risk factors that predict progression to clinically overt cardiovascular disease or progression of the 
subclinical disease. The cohort is a diverse, population-based sample of 6,814 asymptomatic men and women 
aged 45-84. Approximately 38 percent of the recruited participants are white, 28 percent African-American, 22 
percent Hispanic, and 12 percent Asian (predominantly of Chinese descent). Participants were recruited during 
2000-2002 from 6 field centers across the U.S. (at Wake Forest University; Columbia University; Johns 
Hopkins University; the University of Minnesota; Northwestern University; and the University of California – 
Los Angeles). All underwent anthropomorphic measurement and extensive evaluation by questionnaires at 
baseline, followed by 4 subsequent examinations at intervals of approximately 2-4 years. Age and sex were self-
reported. ECGs were recorded in the supine position after a period of rest. ECG data were collected using GE 
MAC 1200 electrocardiographs. Digitally collected ECGs were transferred via phone lines to the MESA ECG 
center (EPICARE). The ECGs were automatically processed by use of GE Marquette 12-SL software (2001 
version), after visual inspection of the recordings for quality. 
 
NEO 
The Netherlands Epidemiology of Obesity (NEO) study21: The NEO was designed for extensive phenotyping to 
investigate pathways that lead to obesity-related diseases. The NEO study is a population-based, prospective 
cohort study that includes 6,671 individuals aged 45–65 years, with an oversampling of individuals with 
overweight or obesity. At baseline, information on demography, lifestyle, and medical history have been 
collected by questionnaires. In addition, samples of 24-h urine, fasting and postprandial blood plasma and 
serum, and DNA were collected. Genotyping was performed using the Illumina HumanCoreExome chip, which 
was subsequently imputed to the 1000 genome reference panel. Participants underwent an extensive physical 
examination, including anthropometry, electrocardiography, spirometry, and measurement of the carotid artery 
intima-media thickness by ultrasonography. In random subsamples of participants, magnetic resonance imaging 
of abdominal fat, pulse wave velocity of the aorta, heart, and brain, magnetic resonance spectroscopy of the 
liver, indirect calorimetry, dual energy X-ray absorptiometry, or accelerometry measurements were performed. 
The collection of data started in September 2008 and completed at the end of September 2012. Participants are 
currently being followed for the incidence of obesity-related diseases and mortality. 
 
RS 
The Rotterdam Study22 is a prospective cohort study in the Ommoord district in the city of Rotterdam, the 
Netherlands. Following the pilot in 1989, recruitment started in January 1990. The main objectives of the 
Rotterdam Study were to investigate the risk factors of cardiovascular, neurological, ophthalmological and 
endocrine diseases in the elderly. Up to 2008, approximately 15,000 subjects aged 45 years or over have been 
recruited. Participants were interviewed at home and went through an extensive set of examinations, bone 
mineral densiometry, including sample collections for in-depth molecular and genetic analyses. Examinations 
were repeated every 3-4 years in potentially changing characteristics. Participants were followed for the most 
common diseases in the elderly, including coronary heart disease, heart failure and stroke, Parkinson's disease, 
Alzheimer's disease and other dementias, depression and anxiety disorders, macular degeneration and 
glaucoma, diabetes mellitus and osteoporosis. 
 
SHIP 
The Study of Health In Pomerania23 is a prospective longitudinal population-based cohort study in Western 
Pomerania assessing the prevalence and incidence of common diseases and their risk factors. SHIP 
encompasses the two independent cohorts SHIP and SHIP-TREND. Participants aged 20 to 79 with German 
citizenship and principal residency in the study area were recruited from a random sample of residents living in 
the three local cities, 12 towns as well as 17 randomly selected smaller towns. Individuals were randomly 
selected stratified by age and sex in proportion to population size of the city, town or small towns, respectively. 
A total of 4,308 participants were recruited between 1997 and 2001 in the SHIP cohort. Between 2008 and 2012 
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a total of 4,420 participants were recruited in the SHIP-TREND cohort. Individuals were invited to the SHIP 
study centre for a computer-assisted personal interviews and extensive physical examinations. 
 
TwinsUK 
TwinsUK24 is a nation-wide registry of volunteer twins in the United Kingdom, with about 12,000 registered 
twins (83% female, equal number of monozygotic and dizygotic twins, predominantly middle-aged and older). 
Over the last 20 years, questionnaire and blood/urine/tissue samples have been collected on over 7,000 subjects, 
as well as three comprehensive phenotyping assessments in the clinical facilities of the Department of Twin 
Research and Genetic Epidemiology, King's College London. The primary focus of study has been the genetic 
basis of healthy aging process and complex diseases, including cardiovascular, metabolic, musculoskeletal, and 
ophthalmologic disorders. Alongside the detailed clinical, biochemical, behavioral, and socio-economic 
characterization of the study population, the major strength of TwinsUK is availability of several 'omics' 
technologies for the participants. These include genome-wide scans of single nucleotide variants, next-
generation sequencing, exome sequencing, epigenetic markers (MeDIP sequencing), gene expression arrays and 
RNA sequencing, telomere length measures, metabolomic profiles, and gut flora microbiomics. 
 
UHP 
The Utrecht Health Project (UHP)25 is an ongoing dynamic population study initiated in a newly developed 
large residential area in Leidsche Rijn, part of the city of Utrecht. All new inhabitants were invited by their 
general practitioner to participate in the UHP. Written informed consent was obtained and an individual health 
profile (IHP) was made by dedicated research nurses. The UHP study was approved by the Medical Ethical 
Committee of the University Medical Center, Utrecht, The Netherlands. A large number of measures were 
taken, including anthropomorphic and blood pressure measurements, andeach participant filled out a 
questionnaire. A 12-lead ECG was made at rest and digitally stored. PR, QRS, QT, and RR intervals were 
calculated automatically. 
 
WHI 
The Women's Health Iniative (WHI)26,27 is a long-term national health study that has focused on strategies for 
preventing heart disease, breast and colorectal cancers, and osteoporotic fractures in postmenopausal women. 
The WHI was designed as a set of randomized controlled clinical trials (CTs) and an observational study (OS). 
The CT (n = 68,132) included 3 overlapping components: the hormone therapy trials (n = 27,347), dietary 
modification trial (n = 48,835), and calcium and vitamin D trial (n = 36,282). Eligible women could be part of 
several of the CT components. Women who were ineligible or unwilling to join the CT were invited to join the 
OS (n = 93,676). All participants in the CT were administered ECGs every three years. In the current paper we 
include the baseline ECGs of women who were genotyped on the ExomeChip. 
 
YFS 
The YFS28 is a population-based follow up-study started in 1980. The main aim of the YFS is to determine the 
contribution made by childhood lifestyle, biological and psychological measures to the risk of cardiovascular 
diseases in adulthood. In 1980, over 3,500 children and adolescents all around Finland participated in the 
baseline study. The follow-up studies have been conducted mainly with 3-year intervals. The latest 30-year 
follow-up study was conducted in 2010-11 (ages 33-49 years) with 2,063 participants. The study was approved 
by the local ethics committees (University Hospitals of Helsinki, Turku, Tampere, Kuopio and Oulu) and was 
conducted following the guidelines of the Declaration of Helsinki. All participants gave their written informed.  
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Ethics Statements 
AGES 
The study is approved by the Icelandic National Bioethics Committee, (VSN: 00–063) and the Data Protection 
Authority.  
 
ARIC 
Institutional Review Board approvals were obtained by each participating ARIC study center (the Universities 
of NC, MS, MN, and John Hopkins University) and the coordinating center (University of NC), and the 
research was conducted in accordance with the principles described in the Helsinki Declaration. All subjects in 
the ARIC study gave informed consent. For more information see dbGaP Study Accession: phs000280.v2.p1. 
JHSPH IRB number H.34.99.07.02.A1. Manuscript proposal number MS2572. 
 
BRIGHT 
All subjects in the BRIGHT study participated as volunteers and were recruited via hypertension registers from 
the MRC General Practice Framework in the UK. Ethics Committee approval was obtained from the multi- and 
local research committees of the partner institutes, and all participants gave written informed consent. 
 
CAMP 
The Institutional Review Board at MGH reviews the study protocol annually. Each participant provided written, 
informed consent prior to enrollment. 
 
CHS 
CHS was approved by institutional review committees at each site, the subjects gave informed consent, and 
those included in the present analysis consented to the use of their genetic information for the study of 
cardiovascular disease. It is the position of the UW IRB that these studies of de-identified data, with no patient 
contact, do not constitute human subjects research. Therefore we have neither an approval number, nor an 
exemption. 
 
ERF 
The Medical Ethics Committee of the Erasmus University Medical Center approved the ERF study protocol and 
all participants, or their legal representatives, provided written informed consent. 
 
FHS 
The Boston University Medical Campus Institutional Review Board approved the FHS genome-wide 
genotyping (protocol number H-226671). 
 
Generation Scotland 
Data was collected for GS:SFHS between 2006 and 2011 with ethical approval from the NHS Tayside 
Committee on Medical Research Ethics A (ref 05/S1401/89). All participants gave written informed consent. 
GS:SFHS is now a Research Tissue Bank approved by the East of Scotland Research Ethics Service (ref 
15/ES/0040). 
 
GOCHA 
The Institutional Review Board at MGH reviewed and approved the study. Participants or their next of kin 
provided informed consent at the time of enrollment. 
 
GRAPHIC 
GRAPHIC was approved by the Leicestershire Research Ethics Committee (LREC Ref N. 6463). 
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Inter99 
Written informed consent was obtained from all participants and the study was approved by the Scientific 
Ethics Committee of the Capital Region of Denmark (KA98155, H-3-2012-155) and was in accordance with the 
principles of the Declaration of Helsinki II. 
 
JHS 
Written informed consent was obtained from all participants. The Jackson Heart Study is conducted with 
approval of the Institutional Review Board of the University of Mississippi Medical Center, DHHS FWA 
#00003630. 
 
KORA 
Written informed consent was obtained from all participants and the study was approved by the local ethics 
committee (Bayerische Landesärztekammer). 
 
KORCULA 
Ethical approval was given for recruitment of all Korcula study participants by ethics committees in both 
Scotland and Croatia. All volunteers gave informed consent prior to participation. 
 
Lifelines 
The Lifelines study followed the recommendations of the Declaration of Helsinki and was in accordance with 
research code of the University Medical Center Groningen (UMCG). The LifeLines study is approved by the 
medical ethical committee of the UMCG, the Netherlands. All participants signed an informed consent form 
before they received an invitation for the physical examination. For a comprehensive overview of the data 
collection, please visit the LifeLines catalogue at www.LifeLines.net. 
 
MESA 
All MESA participants provided written and informed consent to participate in genetic studies. All study sites 
received approval to conduct this research from local Institutional Review Boards at: Columbia University (for 
the MESA New York Field Center), Johns Hopkins University (for the MESA Baltimore Field Center), 
Northwestern University (for the MESA Chicago Field Center), University of California, Los Angeles (for the 
MESA Los Angeles Field Center), University of Minnesota (for the MESA Twin Cities Field Center), Wake 
Forest University Health Sciences Center (for the MESA Winston-Salem Field Center). 
 
NEO 
The Netherlands Epidemiology of obesity (NEO) study is supported by the participating Departments, the 
Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, 
Research Profile Area Vascular and Regenerative Medicine. All participants gave written informed consent and 
the Medical Ethical Committee of the Leiden University Medical Center (LUMC) approved the study design. 
 
RS 
The Rotterdam Study has been approved by the medical ethics committee according to the Population Study 
Act Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. A written 
informed consent was obtained from all participants. 
 
SHIP 
The SHIP study followed the recommendations of the Declaration of Helsinki. The study protocol of SHIP was 
approved by the medical ethics committee of the University of Greifswald. Written informed consent was 
obtained from each of the study participants. The SHIP study is described in PMID: 20167617. 
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TwinsUK 
The study has ethical approval from the NRES Committee London–Westminster, London, UK (EC04/015). 
Written consent was obtained from all participants. Research was carried out in accordance with the Helsinki 
declaration. 
 
UHP 
The Utrecht Health Project has been approved by the Medical Ethics Committee of the University Medical 
Centre Utrecht. All participants give written informed consent. The masking of all personal data for researchers 
and for other possible users of UHP has been regulated in a legal document. 
 
WHI 
All WHI participants provided written and informed consent. All study sites received approval to conduct this 
research from local Institutional Review Boards at the Fred Hutchinson Cancer research Center. 
 
YFS 
The Young Finns Study was approved by the local ethics committees (University Hospitals of Helsinki, Turku, 
Tampere, Kuopio and Oulu) and was conducted following the guidelines of the Declaration of Helsinki. All 
participants gave their written informed consent. 
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Division of Scientific Programs (IAA Y2-DC_1004-02). The study is approved by the Icelandic National 
Bioethics Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to 
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The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT 
nursing team. This work forms part of the research themes contributing to the translational research portfolio for 
the NIHR Barts Cardiovascular Biomedical Research Unit. N.J.S. holds a British Heart Foundation Chair of 
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Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research 
Center. 
 
ERF 
The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by 
European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding 
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Generation Scotland 
Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health 
Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples 
was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, 
Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust 
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School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which 
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GOCHA 
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by grants R01NS073344, R01NS059727, and 5K23NS059774 from the NIH–National Institute of Neurological 
Disorders and Stroke (NIH-NINDS)  
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The GRAPHIC study was funded by the BHF. 
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Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association. The Novo Nordisk 
Foundation Center for Basic Metabolic Research is an independent Research Center at the University of 
Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation 
(www.metabol.ku.dk). 
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Education and Sports research grant (216-1080315-0302) and the Croatian Science Foundation (grant 8875). 
We would like to acknowledge the staff of several institutions in Croatia that supported the field work, 
including but not limited to The University of Split and Zagreb Medical Schools and Croatian Institute for 
Public Health. The SNP genotyping for the KORCULA cohort was performed in Helmholtz Zentrum München, 
Neuherberg, Germany 
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The LifeLines Cohort Study, and generation and management of GWAS genotype data for the LifeLines Cohort 
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Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the 
Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern 
Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center 
Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. 
Niek Verweij is supported by ICIN-NHI and Marie Sklodowska-Curie GF (call: H2020-MSCA-IF-2014, 
Project ID: 661395). 
We thank Behrooz Alizadeh, Annemieke Boesjes, Marcel Bruinenberg, Noortje Festen, Ilja Nolte, Lude Franke, 
Mitra Valimohammadi for their help in creating the GWAS database, and Rob Bieringa, Joost Keers, René 
Oostergo, Rosalie Visser, Judith Vonk for their work related to data-collection and validation. The authors are 
grateful to the study participants, the staff from the LifeLines Cohort Study and Medical Biobank Northern 
Netherlands, and the participating general practitioners and pharmacists. LifeLines Scientific Protocol 
Preparation: Rudolf de Boer, Hans Hillege, Melanie van der Klauw, Gerjan Navis, Hans Ormel, Dirkje Postma, 
Judith Rosmalen, Joris Slaets, Ronald Stolk, Bruce Wolffenbuttel; LifeLines GWAS Working Group: Behrooz 
Alizadeh, Marike Boezen, Marcel Bruinenberg, Noortje Festen, Lude Franke, Pim van der Harst, Gerjan Navis, 
Dirkje Postma, Harold Snieder, Cisca Wijmenga, Bruce Wolffenbuttel. The authors wish to acknowledge the 
services of the LifeLines Cohort Study, the contributing research centres delivering data to LifeLines, and all 
the study participants. 
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This research was supported by the Multi-Ethnic Study of Atherosclerosis (MESA) contracts 
HHSN2682015000031, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, 
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N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and by 
grants UL1-TR-000040, UL1-TR-001079, and UL1-RR-025005 from NCRR. Funding for MESA SHARe 
genotyping was provided by NHLBI Contract N02-HL-6-4278. The provision of genotyping data was supported 
in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the 
National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant 
DK063491 to the Southern California Diabetes Endocrinology Research Center. 
 
NEO 
The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in 
Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for 
collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge 
for the coordination, lab and data management of the NEO study. The genotyping in the NEO study was 
supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO 
study is supported by the participating Departments, the Division and the Board of Directors of the Leiden 
University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative 
Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 
916.14.023). 
 
RS 
The generation and management of the Illumina exome chip v1.0 array data for the Rotterdam Study (RS-I) was 
executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, 
Erasmus MC, Rotterdam, The Netherlands. The Exome chip array data set was funded by the Genetic 
Laboratory of the Department of Internal Medicine, Erasmus MC, from the Netherlands Genomics Initiative 
(NGI)/Netherlands Organisation for Scientific Research (NWO)-sponsored Netherlands Consortium for Healthy 
Aging (NCHA; project nr. 050-060-810); the Netherlands Organization for Scientific Research (NWO; project 
number 184021007) and by the Rainbow Project (RP10; Netherlands Exome Chip Project) of the Biobanking 
and Biomolecular Research Infrastructure Netherlands (BBMRI-NL; www.bbmri.nl ). We thank Ms. Mila 
Jhamai, Ms. Sarah Higgins, and Mr. Marijn Verkerk for their help in creating the exome chip database, and 
Carolina Medina-Gomez, MSc, Lennard Karsten, MSc, and Linda Broer PhD for QC and variant calling. 
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Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), 
the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the 
Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of 
Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the 
participating general practitioners and pharmacists. 
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Community Medicine Research net (CMR) of the Ernst-Moritz-Arndt University Greifswald (EMAU) which is 
funded by the BMBF as well as the Ministry for Education, Science and Culture and the Ministry of Labor, 
Equal Opportunities, and Social Affairs of the Federal State of Mecklenburg-West Pomerania. The CMR 
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generation of the SNP data. 
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Supplemental Table 1: Clinical Characteristics Summary Statistics and Genotyping Information for Each Cohort 
 
Short Name AGES ARIC – EA ARIC – AA BRIGHT CAMP CHS – EA CHS – AA 
Long Name 
Age, 
Gene/Environment 
Susceptibility Study 
The Atherosclerosis 
Risk in Communities 
Study 
The Atherosclerosis 
Risk in Communities 
Study 
British Genetics of 
Hypertension 
MGH Cardiology and 
Metabolic Patient 
Cohort 
The Cardiovascular 
Health Study 
The Cardiovascular 
Health Study 
N, after exclusion 2381 10,246 3567 821 2873 3363 648 
Sex, women, % 61.74 53.85 62.88 60.9 41.7 59.41 64.51 
Age, years, mean±SD 76.12±5.405 54.2±5.683 53.37±5.788 57.54±10.65 61.6±11.4 72.42 ( 5.43 ) 72.57 ( 5.64 ) 
Age, min-max 66-95 44-66 44-66 22-85 31-81 65-100 65-93 
Height, cm, mean±SD 166.4±9.152 168.5±9.394 167.9±8.876 165.9±9.05 171.5±10.1 164.6 ( 9.36 ) 164.27 ( 9.08 ) 
BMI, kg/m2, mean±SD 27.09±4.464 26.99±4.862 29.59±6.17 27.42±3.84 28.75±5.85 26.32 ( 4.48 ) 28.48 ( 5.5 ) 
Heart rate, bpm, mean±SD 66.45±11.38 66.15±9.815 66.58±11.01 63.97±11.5 66.82±12.10 64.36 ( 10.23 ) 67.51 ( 11.49 ) 
QT interval, ms, mean±SD 405.3±34.47 398.8±28.97 400±33.01 421.9±24.4 417.15±23.00 414.99 ( 32.22 ) 407.28 ( 34.96 ) 
QT interval, ms, min-max 292-584 288-646 308-696 363-531 336-574 308-544 312-540 
JT interval, ms, mean±SD 314±33.49 307.6±28.67 310±32.48 328.4±23.97 327.97±24.71 326.16 ( 31.47 ) 319.56 ( 34.87 ) 
JT interval, ms, min-max 214-492 208-556 212-612 266-448 253-482 212-452 216-456 
Study design Population-based Population-based Population-based Hypertensive Cases Population-based Population-based Population-based 
Ethnicity and origin White Europeans Americans with European Ancestry 
Americans with 
African Ancestry 
White Europeans 
from UK European Ancestry 
Americans with 
European Ancestry 
Americans with 
African Ancestry 
Exome Chip version “1.0” “1.0” “1.0” “1.0” 
Infinium 
HumanCoreExome-
24 BeadChips 
“1.0” “1.0” 
Genotype calling software centrally at CHARGE centrally at CHARGE centrally at CHARGE GenCall + zCall GeneCall + zCall centrally at CHARGE centrally at CHARGE 
Quality Control centrally at CHARGE centrally at CHARGE centrally at CHARGE 
followed Oxford's 
"ExomeChip_QC_SO
P_v5" protocol 
SNP call rate ≥95%, 
HWE P≥1E-6 centrally at CHARGE centrally at CHARGE 
Related individuals (yes/no) No No No No No No No 
Familial adjustment N/A N/A N/A N/A N/A N/A N/A 
Principals Components (PCs)  2  10  10  10  10  10  10  
Analysis software  seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta (1.3) seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 
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Short Name ERF FHS GS:SFHS GOCHA GRAPHIC Inter99 
Long Name 
Erasmus 
Rucphen Family 
Study 
Framingham Heart 
Study 
Generation Scotland: 
Scottish Family Health 
Study 
Genetics of Cerebral Hemorrhage 
with Anticoagulation 
The Genetic 
Regulation of Arterial 
Pressure of Humans 
in the Community 
Inter99 
N, after exclusion 965 7062 9027 360 1736 5695 
Sex, women, % 55.23 54.87 59.3 195 (54.2) 49.06 52.1 
Age, years, mean±SD 48.14 (14.30) 39.33±9.87 51.83, 13.57 73.2±8.3 39.07±14.52 46.2±7.9 
Age, min-max 16.65 - 85.27 19-72 18-80 48-100 18-61 29.7-61.3 
Height, cm, mean±SD 167.60 (9.48) 168.93±9.54 167.6, 9.54 168.5±10.5 171.08±9.47 172.2±9.1 
BMI, kg/m2, mean±SD 26.82 (4.59) 26.10±4.98 26.95, 5.17 26.1±4.6 26.03±4.62 26.3±4.7 
Heart rate, bpm, mean±SD 62.89 (10.41) 68.97±13.64 69.65, 11.36 68.3±13.7 66.0±10.34 67.0±10.9 
QT interval, ms, mean±SD 398.82 (28.20) 393.19±36.77 405.92, 30.99 428.6±30.6 404.05±19.91 403.5±26.8 
QT interval, ms, min-max 304 - 520 260-610 304-552 373-667 343-469 310-538 
JT interval, ms, mean±SD 301.37 (27.34) 328±30 316.49, 30.56 N/A 301.80±27.88 312.5±26.7 
JT interval, ms, min-max 200 - 408 217-511 216-464 N/A 228-406 228-436 
Study design 
Population-
based family Population-based 
Population-based with 
families Population-based Population-based Population-based 
Ethnicity and origin European 
Americans with 
European Ancestry 
European-ancestry from 
Scotland Americans with European Ancestry European Caucasian European 
Exome Chip version “1.1” “1.0” Exome8v1-2_A/8v1_A “1.0” “1.0” “1.0” 
Genotype calling software zCall centrally at CHARGE Beadstudio-Gencall v3.0 zCall at Broad GenCall + zCall GenCall + zCall 
Quality Control 
using CHARGE 
recommendatio
n 
centrally at CHARGE 
ID call rate >97%, SNP call 
rate >98%, HWE cutoff 
<1E-6 
sample call rate ≤98%; IBD allele 
sharing pi-hat>0.185; SNV call rate 
<95%; mean heterozygosity >±3 SD; 
HWE p<1×10-6 in controls; differential 
missingness in cases and controls  
using CHARGE 
recommendations 
SNP call rate 
>98%; HWE P>10-
4; cryptic 
relatedness (>20 
individuals) 
Related individuals (yes/no) Yes Yes Yes No Yes No 
Familial adjustment  kinship matrix  famSKAT Kinship matrix N/A Kinship matrix N/A 
Principals Components (PCs)  N/A 10  N/A 2  N/A 10  
Analysis software  seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.5 seqMeta v1.5.0 seqMeta seqMeta v1.5 
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Short Name JHS KORA CROATIA-Korcula Lifelines MESA – EA MESA – AA MESA – HA 
Long Name 
The Jackson Heart 
Study 
Kooperative 
Gesundheitsforschu
ng in der Region 
Augsburg 
CROATIA-Korcula The Lifelines Cohort Study 
Multi-Ethnic Study 
of Atherosclerosis 
(MESA) Cohort 
Multi-Ethnic Study 
of Atherosclerosis 
(MESA) Cohort 
Multi-Ethnic Study 
of Atherosclerosis 
(MESA) Cohort 
N, after exclusion 2216 2672 295 1943 2324 1501 1382 
Sex, women, % 62.54 52.3 62.4 59.59 53.7 54.9 52.6 
Age, years, mean±SD 53.06±12.69 48.8±13.1 54.23, 13.38 45.27±13.09 62.36±10.17 62.06±10.03 61.16±10.24 
Age, min-max 21-91 25-74 18-88 18-87 44-84 45-84 44-84 
Height, cm, mean±SD 169.35±9.34 168.3±9.3 168.3, 8.91 174.66±9.32 168.4±9.266 168.36±9.52 161.68±9.34 
BMI, kg/m2, mean±SD 31.34±6.42 27.0±4.4 27.99, 4.24 25.89±4.55 27.66±5.354 30.1±5.88 29.5±5.15 
Heart rate, bpm, mean±SD 68.39±10.14 65.1±10.2 65.85, 9.44 68.65±11.06 66.26±10.14 63.01±10.28 63.5±9.39 
QT interval, ms, mean±SD 414.14±31.62 407.5±26.7 401.64, 29.44 393.53±26.89 399.1±30.07 410.33±31.73 408.8±29.75 
QT interval, ms, min-max 290-580 316-542 270.0-510.0 289-525 334-538 320-512 328-530 
JT interval, ms, mean±SD 320.37±30.46 315.7±26.6 305.79, 29.36 299.92±26.79 319.32±28.65 319.4±30.99 317.79±29.42 
JT interval, ms, min-max 212-466 234-442 176.0-408.0 202-415 240-438 240-420 238-428 
Study design 
Mixed family and 
population-based Population-based Isolate population Population-based Population-based Population-based Population-based 
Ethnicity and origin African American 
European / 
Germany European Ancestry  
European, 
Netherlands European Ancestry African American Hispanic 
Exome Chip version “1.0” “1.0” 12v1_A “1.1” “1.0” “1.0” “1.0” 
Genotype calling software centrally at CHARGE GeneCall + zCall GenCall v3.0 GeneCall + zCall centrally at CHARGE centrally at CHARGE centrally at CHARGE 
Quality Control centrally at CHARGE 
pairwise exclusion 
of samples with 
PI_HAT>0.1875 
ID call rate >97%, 
SNP call rate filter 
98%, HWE cutoff 
<1E-6 
SNP Callrate ≥95%; 
HWE >10-6; sample 
exclusion callrate 
<95%; PCA outliers 
centrally at CHARGE centrally at CHARGE centrally at CHARGE 
Related individuals (yes/no) Yes No Yes No No No No 
Familial adjustment Kinship matrix N/A Kinship matrix N/A N/A N/A N/A 
Principals Components (PCs)  10   N/A 5  2  2  2  
Analysis software  seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.5 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 
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Short Name MESA – CH NEO RS SHIP TwinsUK 
Long Name 
Multi-Ethnic Study 
of Atherosclerosis 
(MESA) Cohort 
The Netherlands 
Epidemiology of 
Obesity (NEO) Study 
The Rotterdam 
Elderly Study 
Study of Health In 
Pomerania TwinsUK 
N, after exclusion 750 6047 2419 6224 466 
Sex, women, % 51.6 52.03 55.25 52.52 93.56 
Age, years, mean±SD 62.21±10.37 56.0±5.94 68.6±8.363 49.56±15.32 52.08±11.65 
Age, min-max 44-84 44-66 55-101 20-82 18-83 
Height, cm, mean±SD 161.49±8.58 173.62±9.59 167.5±9.384 169.54±9.31 163.2±6.930 
BMI, kg/m2, mean±SD 23.99±3.29 30.05±4.82 26.21±3.591 27.57±4.98 26.72±5.328 
Heart rate, bpm, mean±SD 63.06±8.63 65.7±11.39 70.73±12.28 NA 66.63±10.45 
QT interval, ms, mean±SD 410.97±29.38 406.6±30.5 396.7±29.197 406.82±28.43 403.2±27.81 
QT interval, ms, min-max 334-554 244-666 282-524 308-540 308-500 
JT interval, ms, mean±SD 321.67±29.55 312.9±28.7 299.82±28.158 312.15±29.36 315.2±27.37 
JT interval, ms, min-max 256-450 188-484 196-416 212-436 228-402 
Study design Population-based Population-based Population-based Population-based Twin study 
Ethnicity and origin 
Chinese American 
European Ancenstry 
from the 
Netherlands 
Europeans with 
European Ancestry EA from Germany 
European ancestry, individuals from the 
United Kingdom 
Exome Chip version “1.0” 24v1-0 “1.0” “1.0” “1.0” 
Genotype calling software centrally at CHARGE GenCall centrally at CHARGE GenCall + zCall Gencall 
Quality Control centrally at CHARGE 
Outlying individuals 
were excluded on 
the basis of 
relatedness, non-
European ancestry, 
sex discrepancy and 
heterzygosity 
centrally at CHARGE 
Samples: Genotype call rate 
<98%; high heterozygosity; 
high cryptic relatedness; IBS 
clustering; sex mismatches 
Variants: call rate <95%; 
HWE p-value <10E-4 
Excluded samples with callrate <97%; 
autosomal heterozygosity outliers (+/- 4SD); 
ethnic outliers from 1000 Genomes Project 
data (PCA); GWAS concordance (when 
available). Removed variants with call rate 
<95% and pHWE< 1x10-6. 
Related individuals (yes/no) No No No No No 
Familial adjustment N/A N/A N/A N/A N/A 
Principals Components (PCs)  2  10  5  10  10  
Analysis software  seqMeta v1.6.0 seqMeta v1.5 seqMeta v1.6.0 
seqMeta v1.4.0 (seqMeta 
v1.3.0 for QT analysis) seqMeta v1.3 
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Short Name UHP WHI – EA WHI – AA YFS 
Long Name Utrecht Health Project 
The Women's Health 
Initiative 
The Women's Health 
Initiative 
The Cardiovascular Risk in Young 
Finns Study 
N, after exclusion 1731 13450 1678 1784 
Sex, women, % 55 100 100 55.72 
Age, years, mean±SD 39.10±12.956 66.1±6.547 64.55±6.46 41.92±4.98 
Age, min-max 18-91 50-81 50-79 34-49 
Height, cm, mean±SD 174.78±9.779 161.5±6.6.307 161.9±6.708 172.04±9.22 
BMI, kg/m2, mean±SD 24.90±3.875 28.70±5.637 31.13±5.85 26.45±4.94 
Heart rate, bpm, mean±SD 64.60±10.612 66.56±10.125 66.77±10.84 60.04±9.47 
QT interval, ms, mean±SD 403.48±27.422 401.399±29.9322 402.23±31.77 415.11±33.54 
QT interval, ms, min-max 308-512 290-624 310-520 284-636 
JT interval, ms, mean±SD 306.65±27.054 315.2±29.49 317.13±30.85 324.66±33.47 
JT interval, ms, min-max 216-402 204-534 218-426 206-564 
Study design Population-based Population-based Population-based Population-based 
Ethnicity and origin Dutch citizens of European Ancestry 
Americans with European 
Ancestry 
Americans with African 
Ancestry Finnish with European Ancestry 
Exome Chip version 1.1 “1.0” “1.0” CoreExome v1.0 
Genotype calling software GenomeStudio and zCall   GenomeStudio 
Quality Control 
Plink v1.07 was used for QC. Samples with 
missing SNP rate >5% or discordant sex 
were excluded. Using SNPs with 
missingness<1%, MAF>5%, Hardy-Weinberg 
P<0.001, LD-pruned r2>0.2, we removed 
samples with heterozygosity >4 SD, related 
samples randomly, and samples from non-
European descent based on manual 
inspection of PCA results. SNPs with missing 
>5% or HWE P<0.001 were removed.   
SNP and sample call-rate 95%, 
excess heterozygosity, cryptic 
relatedness, MDS outliers 
Related individuals (yes/no) No No No No 
Familial adjustment N/A N/A N/A N/A 
Principals Components (PCs)  1 PC 2 PCs 2 PCs 4 PCs 
Analysis software  seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.3.0 
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Supplemental Table 2: ExomeChip-wide Significant Variants in QT Meta-analysis 
       Combined 
Locus Name SNV Chr Position Gene Functional Category Damaging CAF N P BETA SE 
RNF207 rs709209 1 6,278,414 RNF207 exonic;nonsynonymous 0 0.379 95,626 1.33E-48 1.23 0.09 
RNF207 rs846111 1 6,279,370 RNF207 exonic;nonsynonymous 0 0.241 76,129 1.51E-46 1.51 0.11 
TCEA3 rs1077514 1 23,766,233 ASAP3 intronic 0 0.179 92,753 4.08E-08 -0.58 0.11 
NOS1AP rs6676438 1 161,983,089 OLFML2B intronic 0 0.347 92,753 1.38E-37 1.15 0.09 
NOS1AP rs2880058 1 162,014,632  intergenic 0 0.380 95,626 9.54E-177 2.41 0.09 
NOS1AP rs12143842 1 162,033,890  intergenic 0 0.240 95,626 2.90E-255 3.18 0.10 
NOS1AP rs1415259 1 162,085,309 NOS1AP intronic 0 0.391 92,753 1.14E-145 2.15 0.08 
NOS1AP rs10494366 1 162,085,685 NOS1AP intronic 0 0.391 95,626 2.81E-149 2.15 0.08 
NOS1AP rs16857031 1 162,112,910 NOS1AP intronic 0 0.155 89,579 2.11E-66 1.94 0.12 
NOS1AP rs12029454 1 162,133,117 NOS1AP intronic 0 0.163 95,626 1.15E-123 2.53 0.11 
NOS1AP rs12725553 1 162,168,116 NOS1AP intronic 0 0.412 95,626 5.30E-59 1.34 0.08 
NOS1AP rs4657178 1 162,210,610 NOS1AP intronic 0 0.270 95,626 2.24E-92 1.84 0.09 
ATP1B1 rs10919071 1 169,099,483 ATP1B1 intronic 0 0.115 95,626 2.55E-30 -1.37 0.13 
ATP1B1 rs6027 1 169,483,561 F5 exonic;nonsynonymous 1 0.053 74,803 1.34E-10 -1.27 0.21 
ATP1B1 rs6018 1 169,511,878 F5 exonic;nonsynonymous 0 0.055 73,622 1.20E-09 -1.25 0.21 
ATP1B1 rs6033 1 169,521,853 F5 exonic;nonsynonymous 0 0.066 95,626 1.40E-08 -0.87 0.16 
PM20D1 rs1361754 1 205,801,872 PM20D1 exonic;nonsynonymous 0 0.511 95,626 1.20E-09 0.47 0.08 
TTN-CCDC141 rs72648998 2 179,575,511 TTN exonic;nonsynonymous 0 0.054 95,626 3.20E-09 1.00 0.18 
TTN-CCDC141 rs10497520 2 179,644,855 TTN exonic;nonsynonymous 1 0.184 92,753 8.61E-09 0.63 0.11 
SLC4A3 rs55910611 2 220,500,412 SLC4A3 exonic;nonsynonymous 0 0.006 74,508 1.53E-07 -3.06 0.61 
SCN5A-SCN10A rs116202356 3 38,103,776 DLEC1 exonic;nonsynonymous 0 0.015 95,626 3.08E-11 2.22 0.33 
SCN5A-SCN10A rs11129795 3 38,589,163 SCN5A downstream 0 0.233 95,626 1.07E-23 -0.93 0.10 
SCN5A-SCN10A rs12053903 3 38,593,393 SCN5A intronic 0 0.379 95,626 1.20E-26 -0.88 0.09 
SCN5A-SCN10A rs3922844 3 38,624,253 SCN5A intronic 0 0.336 92,753 1.75E-19 0.82 0.09 
SCN5A-SCN10A rs11708996 3 38,633,923 SCN5A intronic 0 0.135 89,579 7.31E-20 -1.08 0.12 
SCN5A-SCN10A rs1805124 3 38,645,420 SCN5A exonic;nonsynonymous 0 0.238 95,626 7.48E-12 0.66 0.10 
SCN5A-SCN10A rs11710077 3 38,657,899 SCN5A intronic 0 0.191 89,579 4.11E-14 0.78 0.11 
SCN5A-SCN10A rs9851724 3 38,719,935  intergenic 0 0.306 80,498 1.58E-10 0.62 0.10 
SCN5A-SCN10A rs6795970 3 38,766,675 SCN10A exonic;nonsynonymous 0 0.365 95,626 2.55E-17 -0.67 0.09 
SCN5A-SCN10A rs6800541 3 38,774,832 SCN10A intronic 0 0.371 95,626 2.23E-16 -0.66 0.08 
CASR rs1801725 3 122,003,757 CASR exonic;nonsynonymous 0 0.126 95,626 4.30E-08 -0.58 0.12 
SLC4A4 rs7689609 4 72,083,374 SLC4A4 intronic 0 0.212 85,380 3.88E-08 0.64 0.12 
SLC35F1-PLN rs281868 6 118,574,061 SLC35F1 intronic 0 0.487 92,753 1.92E-18 0.66 0.08 
SLC35F1-PLN rs89107 6 118,578,043 SLC35F1 intronic 0 0.490 95,626 4.92E-53 1.19 0.08 
SLC35F1-PLN rs12210810 6 118,653,204  intergenic 0 0.046 89,579 2.11E-35 -2.28 0.20 
SLC35F1-PLN rs11153730 6 118,667,522  intergenic 0 0.467 95,626 4.88E-74 1.41 0.08 
SLC35F1-PLN rs11970286 6 118,680,374  intergenic 0 0.429 95,626 7.86E-61 1.29 0.08 
SLC35F1-PLN rs3734382 6 118,886,961 CEP85L exonic;nonsynonymous 0 0.257 95,626 3.97E-13 -0.63 0.09 
SLC35F1-PLN rs3734381 6 118,887,303 CEP85L exonic;nonsynonymous 0 0.461 91,615 3.75E-36 -1.00 0.08 
CAV1 rs3807989 7 116,186,241 CAV1 intronic 0 0.429 95,626 4.37E-12 0.54 0.08 
KCNH2 rs2968864 7 150,622,162  intergenic 0 0.216 92,753 5.13E-51 -1.48 0.10 
KCNH2 rs2968863 7 150,623,137  intergenic 0 0.216 92,753 3.86E-51 -1.48 0.10 
KCNH2 rs4725982 7 150,637,863  intergenic 0 0.224 95,626 1.16E-46 1.36 0.10 
KCNH2 rs1805123 7 150,645,534 KCNH2 exonic;nonsynonymous 0 0.214 95,626 6.67E-51 -1.47 0.10 
KCNH2 rs3807375 7 150,667,210 KCNH2 intronic 0 0.399 92,753 6.66E-37 1.08 0.08 
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ZNF37A rs2474570 10 38,383,757 ZNF37A intronic 0 0.488 95,626 8.85E-10 -0.48 0.08 
ZNF37A rs4934956 10 38,814,815  intergenic 0 0.497 70,792 2.29E-10 0.58 0.10 
NRAP rs3189030 10 115,393,929 NRAP exonic;nonsynonymous 0 0.299 95,626 3.77E-08 -0.48 0.09 
NRAP rs2185913 10 115,410,234 NRAP exonic;nonsynonymous 1 0.271 95,626 1.92E-07 -0.48 0.09 
KCNQ1 rs800336 11 2,473,131 KCNQ1 intronic 0 0.312 92,753 5.94E-17 -0.77 0.10 
KCNQ1 rs2074238 11 2,484,803 KCNQ1 intronic 0 0.074 89,284 8.22E-130 -3.58 0.16 
KCNQ1 rs12296050 11 2,489,342 KCNQ1 intronic 0 0.228 95,626 8.87E-58 1.57 0.10 
KCNQ1 rs12576239 11 2,502,319 KCNQ1 intronic 0 0.139 95,626 2.10E-40 1.51 0.12 
KCNQ1 rs1080015 11 2,511,527 KCNQ1 intronic 0 0.397 95,626 1.68E-09 0.48 0.08 
KCNQ1 rs179429 11 2,550,730 KCNQ1 intronic 0 0.171 95,626 3.51E-08 -0.59 0.11 
KCNQ1 rs17215500 11 2,790,111 KCNQ1 exonic;stopgain 1 0.000 95,626 1.11E-11 46.38 5.71 
FEN1-FADS2 rs102275 11 61,557,803 C11orf10 intronic 0 0.382 92,753 2.26E-08 -0.43 0.09 
FEN1-FADS2 rs174546 11 61,569,830 FADS1 UTR3 0 0.315 95,626 1.65E-09 -0.48 0.09 
FEN1-FADS2 rs174547 11 61,570,783 FADS1 intronic 0 0.315 95,626 1.65E-09 -0.48 0.09 
FEN1-FADS2 rs174550 11 61,571,478 FADS1 intronic 0 0.315 95,626 1.86E-09 -0.48 0.09 
FEN1-FADS2 rs174570 11 61,597,212 FADS2 intronic 0 0.134 95,626 2.39E-07 -0.58 0.12 
FEN1-FADS2 rs1535 11 61,597,972 FADS2 intronic 0 0.325 95,626 8.28E-10 -0.48 0.09 
FEN1-FADS2 rs174583 11 61,609,750 FADS2 intronic 0 0.344 95,626 4.89E-09 -0.45 0.09 
KLF12 rs1886512 13 74,520,186 KLF12 intronic 0 0.381 80,552 1.53E-10 0.57 0.09 
LITAF rs8049607 16 11,691,753  intergenic 0 0.503 95,626 8.42E-44 1.05 0.08 
MKL2 rs1659127 16 14,388,305  intergenic 0 0.338 30,645 4.49E-08 0.90 0.16 
MKL2 rs30208 16 14,428,853  intergenic 0 0.501 95,626 2.28E-09 0.45 0.08 
CNOT1 rs4356470 16 58,529,615 NDRG4 intronic 0 0.326 95,626 1.37E-20 -0.80 0.09 
CNOT1 rs7188697 16 58,622,178 CNOT1 intronic 0 0.247 91,615 3.78E-63 -1.57 0.10 
LIG3 rs2230553 17 33,269,648 CCT6B exonic;nonsynonymous 1 0.343 89,579 1.65E-10 -0.56 0.09 
LIG3 rs9635769 17 33,288,363 CCT6B exonic;nonsynonymous 0 0.451 95,626 2.77E-08 0.47 0.08 
LIG3 rs2074518 17 33,324,382 LIG3 intronic 0 0.428 92,753 2.16E-21 -0.79 0.08 
GOSR2 rs17608766 17 45,013,271 GOSR2 UTR3 0 0.123 95,626 2.83E-09 0.72 0.12 
PRKCA rs56152251 17 64,280,153  intergenic 0 0.434 95,626 4.89E-11 -0.57 0.08 
PRKCA rs9912468 17 64,318,357 PRKCA intronic 0 0.417 89,579 1.54E-15 -0.68 0.08 
KCNJ2 rs17779747 17 68,494,992  Intergenic 0 0.304 93,948 3.34E-37 -1.08 0.09 
Damaging: loss of function or predicted damaging by at least 2 of the following methods: Polyphen, LRT, 
SIFT, Mutation Taster (1=True, 0=False)[1]. CAF=coded allele frequency; N=sample size; BETA= effect size 
in milliseconds; SE=standard error of effect size estimate. Combined=all ethnicities meta-analysis; 
EA=European ancestry-only meta-analysis; AA=African American-only meta-analysis. 
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Supplemental Table 2: ExomeChip-wide Significant Variants in QT Meta-analysis -Continued- 
  EA  AA  JT Combined 
 SNV CAF N P BETA SE  CAF N P BETA SE  P BETA SE 
 rs709209 0.343 83,884 1.14E-50 1.32 0.09  0.708 9,610 6.38E-02 0.53 0.29  2.03E-52 1.29 0.09 
 rs846111 0.271 64,387 1.55E-49 1.59 0.11  0.057 9,610 7.88E-01 0.22 0.58  6.10E-50 1.60 0.11 
 rs1077514 0.140 81,011 3.11E-09 -0.71 0.13  0.487 9,610 6.30E-01 -0.11 0.27  3.79E-11 -0.71 0.11 
 rs6676438 0.284 81,011 4.37E-37 1.18 0.10  0.858 9,610 3.09E-02 0.93 0.41  4.13E-41 1.21 0.09 
 rs2880058 0.338 83,884 1.68E-181 2.55 0.09  0.718 9,610 2.03E-04 1.23 0.30  1.13E-184 2.48 0.09 
 rs12143842 0.253 83,884 2.10E-258 3.33 0.10  0.123 9,610 3.24E-06 1.78 0.40  2.61E-272 3.32 0.10 
 rs1415259 0.362 81,011 3.62E-155 2.34 0.09  0.614 9,610 5.46E-03 0.84 0.27  1.20E-153 2.23 0.09 
 rs10494366 0.363 83,884 8.80E-159 2.34 0.09  0.614 9,610 6.17E-03 0.84 0.27  2.87E-157 2.23 0.08 
 rs16857031 0.138 77,837 2.45E-70 2.19 0.13  0.292 9,610 5.32E-04 1.05 0.29  1.87E-68 1.99 0.12 
 rs12029454 0.146 83,884 5.37E-134 2.89 0.12  0.285 9,610 8.15E-04 0.92 0.29  1.01E-127 2.60 0.11 
 rs12725553 0.390 83,884 5.75E-60 1.43 0.09  0.586 9,610 2.88E-03 0.81 0.27  1.68E-59 1.36 0.08 
 rs4657178 0.256 83,884 1.52E-104 2.09 0.10  0.358 9,610 5.57E-01 0.24 0.28  1.16E-93 1.88 0.09 
 rs10919071 0.125 83,884 5.21E-32 -1.44 0.13  0.026 9,610 6.40E-01 -0.55 0.84  7.19E-29 -1.36 0.13 
 rs6027 0.058 64,739 3.45E-11 -1.34 0.21  0.012 7,932 3.19E-01 -1.68 1.40  3.54E-11 -1.36 0.21 
 rs6018 0.060 63,558 2.74E-10 -1.33 0.21  0.012 7,932 4.23E-01 -1.43 1.40  1.44E-10 -1.35 0.21 
 rs6033 0.073 83,884 3.28E-09 -0.92 0.17  0.014 9,610 8.79E-01 -0.56 1.15  1.59E-09 -0.94 0.16 
 rs1361754 0.530 83,884 4.41E-10 0.52 0.09  0.407 9,610 9.43E-01 -0.06 0.27  9.75E-06 0.35 0.08 
 rs72648998 0.059 83,884 2.59E-09 1.03 0.18  0.013 9,610 7.57E-01 0.32 1.16  1.91E-09 1.02 0.18 
 rs10497520 0.132 81,011 7.20E-08 0.65 0.13  0.527 9,610 1.78E-01 0.41 0.27  1.28E-08 0.63 0.11 
 rs55910611 0.007 64,444 2.37E-07 -3.03 0.62  0.001 7,932 1.46E-01 -8.71 5.75  6.02E-08 -3.24 0.62 
 rs116202356 0.017 83,884 4.64E-11 2.27 0.34  0.004 9,610 2.18E-01 1.55 2.10  2.49E-18 2.93 0.33 
 rs11129795 0.241 83,884 2.11E-24 -1.00 0.10  0.181 9,610 3.32E-01 -0.14 0.34  3.66E-45 -1.30 0.10 
 rs12053903 0.329 83,884 9.05E-28 -0.95 0.09  0.788 9,610 5.70E-01 -0.11 0.33  4.59E-47 -1.19 0.09 
 rs3922844 0.308 81,011 3.42E-18 0.83 0.09  0.581 9,610 2.96E-03 0.95 0.27  4.19E-38 1.15 0.09 
 rs11708996 0.148 77,837 1.02E-19 -1.10 0.12  0.041 9,610 2.30E-01 -0.78 0.67  6.14E-39 -1.55 0.12 
 rs1805124 0.234 83,884 4.24E-10 0.64 0.10  0.286 9,610 7.07E-03 0.83 0.29  5.26E-25 0.97 0.10 
 rs11710077 0.203 77,837 2.19E-12 0.75 0.11  0.104 9,610 2.76E-03 1.44 0.44  7.19E-31 1.19 0.11 
 rs9851724 0.324 70,434 8.94E-12 0.67 0.10  0.154 7,932 3.86E-01 0.58 0.42  2.96E-23 0.97 0.10 
 rs6795970 0.399 83,884 1.70E-16 -0.67 0.09  0.099 9,610 2.03E-02 -1.23 0.46  1.06E-34 -0.99 0.09 
 rs6800541 0.405 83,884 1.46E-15 -0.65 0.09  0.100 9,610 2.50E-02 -1.20 0.45  4.34E-33 -0.97 0.09 
 rs1801725 0.138 83,884 4.82E-08 -0.59 0.13  0.036 9,610 6.83E-01 -0.28 0.72  2.38E-09 -0.65 0.12 
 rs7689609 0.140 75,316 6.05E-08 0.67 0.13  0.837 7,932 1.83E-02 1.03 0.46  6.81E-08 0.64 0.12 
 rs281868 0.497 81,011 1.55E-18 0.71 0.09  0.444 9,610 1.50E-01 0.29 0.27  8.42E-15 0.59 0.08 
 rs89107 0.500 83,884 5.32E-56 1.30 0.09  0.446 9,610 1.46E-01 0.29 0.27  3.37E-39 1.03 0.08 
 rs12210810 0.052 77,837 1.94E-36 -2.36 0.20  0.010 9,610 1.64E-01 -1.14 1.35  2.81E-31 -2.16 0.20 
 rs11153730 0.494 83,884 1.32E-76 1.51 0.09  0.281 9,610 2.27E-02 0.68 0.29  4.33E-55 1.23 0.08 
 rs11970286 0.457 83,884 3.39E-62 1.36 0.09  0.222 9,610 1.19E-02 0.88 0.32  1.29E-44 1.12 0.08 
 rs3734382 0.251 83,884 1.00E-11 -0.63 0.10  0.248 9,610 7.99E-03 -0.78 0.30  1.72E-08 -0.50 0.09 
 rs3734381 0.457 80,521 6.47E-38 -1.08 0.09  0.442 8,962 7.91E-02 -0.46 0.27  3.22E-25 -0.84 0.08 
 rs3807989 0.406 83,884 3.63E-10 0.51 0.09  0.647 9,610 2.92E-03 0.83 0.28  6.27E-06 0.35 0.08 
 rs2968864 0.239 81,011 1.05E-51 -1.51 0.10  0.046 9,610 7.74E-01 -0.31 0.64  3.67E-52 -1.51 0.10 
 rs2968863 0.239 81,011 1.42E-51 -1.51 0.10  0.051 9,610 5.40E-01 -0.51 0.61  1.97E-52 -1.52 0.10 
 rs4725982 0.214 83,884 2.48E-48 1.50 0.10  0.261 9,610 9.80E-02 0.34 0.31  8.11E-49 1.41 0.10 
 rs1805123 0.236 83,884 7.43E-52 -1.50 0.10  0.046 9,610 9.64E-01 -0.17 0.64  1.06E-51 -1.49 0.10 
 rs3807375 0.357 81,011 6.22E-41 1.21 0.09  0.696 9,610 8.58E-01 -0.11 0.29  5.00E-37 1.10 0.09 
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 rs2474570 0.485 83,884 5.29E-10 -0.52 0.09  0.505 9,610 5.71E-01 -0.17 0.26  7.70E-09 -0.46 0.08 
 rs4934956 0.496 61,376 3.47E-11 0.66 0.10  0.512 7,284 8.14E-01 0.05 0.31  2.92E-08 0.53 0.10 
 rs3189030 0.316 83,884 7.27E-08 -0.49 0.09  0.143 9,610 1.46E-01 -0.56 0.37  2.78E-08 -0.49 0.09 
 rs2185913 0.295 83,884 8.58E-08 -0.50 0.09  0.059 9,610 9.86E-01 -0.09 0.57  6.14E-08 -0.51 0.09 
 rs800336 0.248 81,011 4.42E-18 -0.82 0.10  0.827 9,610 4.85E-01 -0.44 0.36  1.19E-19 -0.84 0.10 
 rs2074238 0.082 77,542 3.01E-127 -3.63 0.16  0.018 9,610 7.51E-04 -2.40 1.02  5.40E-135 -3.72 0.16 
 rs12296050 0.191 83,884 7.54E-64 1.79 0.11  0.523 9,610 7.02E-02 0.51 0.27  1.62E-64 1.66 0.10 
 rs12576239 0.134 83,884 1.41E-48 1.79 0.13  0.177 9,610 7.64E-01 -0.19 0.35  1.96E-46 1.62 0.12 
 rs1080015 0.363 83,884 2.77E-11 0.57 0.09  0.675 9,610 4.93E-01 -0.34 0.28  3.66E-11 0.52 0.09 
 rs179429 0.171 83,884 1.47E-07 -0.58 0.11  0.196 9,610 2.67E-01 -0.54 0.34  1.97E-08 -0.60 0.11 
 rs17215500 0.000 83,884 5.20E-09 43.00 6.31  0.000 9,610 3.55E-04 61.59 13.40  6.24E-12 46.25 5.60 
 rs102275 0.344 81,011 3.98E-09 -0.48 0.09  0.658 9,610 2.77E-01 -0.29 0.28  1.26E-05 -0.33 0.09 
 rs174546 0.336 83,884 5.11E-10 -0.51 0.09  0.082 9,610 2.24E-01 -0.54 0.50  2.24E-06 -0.38 0.09 
 rs174547 0.336 83,884 5.22E-10 -0.51 0.09  0.082 9,610 2.17E-01 -0.54 0.50  2.13E-06 -0.38 0.09 
 rs174550 0.336 83,884 5.70E-10 -0.51 0.09  0.082 9,610 2.24E-01 -0.54 0.50  2.51E-06 -0.38 0.09 
 rs174570 0.135 83,884 5.70E-08 -0.64 0.13  0.041 9,610 1.53E-01 -0.82 0.67  1.18E-05 -0.51 0.12 
 rs1535 0.338 83,884 4.77E-10 -0.51 0.09  0.157 9,610 1.31E-01 -0.45 0.37  7.84E-07 -0.39 0.09 
 rs174583 0.346 83,884 1.99E-09 -0.49 0.09  0.279 9,610 1.21E-01 -0.47 0.30  1.43E-06 -0.37 0.09 
 rs1886512 0.370 68,810 7.74E-11 0.61 0.09  0.471 9,610 3.86E-01 0.33 0.27  1.09E-15 0.71 0.09 
 rs8049607 0.509 83,884 1.13E-41 1.11 0.09  0.454 9,610 9.16E-04 0.68 0.27  5.10E-45 1.08 0.08 
 rs1659127 0.338 30,645 4.49E-08 0.90 0.16  0.000 0 NA NA Inf  7.91E-06 0.72 0.16 
 rs30208 0.510 83,884 1.89E-11 0.53 0.09  0.432 9,610 5.71E-01 -0.12 0.27  4.59E-09 0.44 0.08 
 rs4356470 0.307 83,884 1.37E-22 -0.90 0.09  0.448 9,610 4.08E-01 -0.16 0.27  1.28E-19 -0.79 0.09 
 rs7188697 0.255 80,521 8.49E-65 -1.66 0.10  0.153 8,962 1.53E-02 -0.95 0.37  4.65E-64 -1.60 0.10 
 rs2230553 0.368 77,837 2.90E-10 -0.57 0.09  0.171 9,610 1.91E-01 -0.51 0.35  4.57E-09 -0.53 0.09 
 rs9635769 0.425 83,884 1.72E-08 0.50 0.09  0.686 9,610 8.31E-01 0.04 0.29  2.02E-08 0.48 0.08 
 rs2074518 0.460 81,011 3.60E-20 -0.79 0.09  0.178 9,610 1.49E-02 -0.92 0.35  6.60E-20 -0.78 0.08 
 rs17608766 0.136 83,884 4.63E-09 0.72 0.13  0.026 9,610 1.59E-01 1.08 0.84  7.21E-04 0.43 0.13 
 rs56152251 0.421 83,884 1.58E-09 -0.55 0.09  0.526 9,610 1.56E-02 -0.72 0.27  2.07E-17 -0.72 0.08 
 rs9912468 0.421 77,837 2.56E-12 -0.64 0.09  0.379 9,610 6.40E-05 -1.03 0.28  7.15E-25 -0.87 0.09 
 rs17779747 0.327 83,884 2.32E-37 -1.10 0.09  0.091 7,932 7.36E-03 -1.42 0.54  2.81E-35 -1.08 0.09 
Damaging: loss of function or predicted damaging by at least 2 of the following methods: Polyphen, LRT, 
SIFT, Mutation Taster (1=True, 0=False)[1]. CAF=coded allele frequency; N=sample size; BETA= effect size 
in milliseconds; SE=standard error of effect size estimate. Combined=all ethnicities meta-analysis; 
EA=European ancestry-only meta-analysis; AA=African American-only meta-analysis. 
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Supplemental Table 3: ExomeChip-wide Significant Variants in JT Meta-analysis 
       Combined 
Locus Name SNV Chr Pos Gene Functiional Category Damaging CAF N P BETA SE 
RNF207 rs709209 1 6,278,414 RNF207 exonic;nonsynonymous 0 0.380 92,046 2.03E-52 1.29 0.09 
RNF207 rs200882245 1 6,279,316 RNF207 exonic;nonsynonymous 0 0.002 92,046 2.06E-08 -4.56 0.85 
RNF207 rs846111 1 6,279,370 RNF207 exonic;nonsynonymous 0 0.240 72,859 6.10E-50 1.60 0.11 
TCEA3 rs627304 1 23,537,555  intergenic 0 0.434 92,046 1.90E-07 -0.40 0.08 
TCEA3 rs3889814 1 23,731,819 TCEA3 intronic 0 0.202 89,173 8.82E-08 -0.59 0.12 
TCEA3 rs1077514 1 23,766,233 ASAP3 intronic 0 0.180 89,173 3.79E-11 -0.71 0.11 
NOS1AP rs6676438 1 161,983,089 OLFML2B intronic 0 0.349 89,173 4.13E-41 1.21 0.09 
NOS1AP rs2880058 1 162,014,632  intergenic 0 0.381 92,046 1.13E-184 2.48 0.09 
NOS1AP rs12143842 1 162,033,890  intergenic 0 0.239 92,046 2.61E-272 3.32 0.10 
NOS1AP rs1415259 1 162,085,309 NOS1AP intronic 0 0.392 89,173 1.20E-153 2.23 0.09 
NOS1AP rs10494366 1 162,085,685 NOS1AP intronic 0 0.392 92,046 2.87E-157 2.23 0.08 
NOS1AP rs16857031 1 162,112,910 NOS1AP intronic 0 0.155 86,309 1.87E-68 1.99 0.12 
NOS1AP rs12029454 1 162,133,117 NOS1AP intronic 0 0.164 92,046 1.01E-127 2.60 0.11 
NOS1AP rs12725553 1 162,168,116 NOS1AP intronic 0 0.412 92,046 1.68E-59 1.36 0.08 
NOS1AP rs4657178 1 162,210,610 NOS1AP intronic 0 0.270 92,046 1.16E-93 1.88 0.09 
ATP1B1 rs10919071 1 169,099,483 ATP1B1 intronic 0 0.115 92,046 7.19E-29 -1.36 0.13 
ATP1B1 rs6027 1 169,483,561 F5 exonic;nonsynonymous 1 0.053 71,223 3.54E-11 -1.36 0.21 
ATP1B1 rs6018 1 169,511,878 F5 exonic;nonsynonymous 0 0.054 70,404 1.44E-10 -1.35 0.21 
ATP1B1 rs6037 1 169,513,583 F5 exonic;synonymous 0 0.068 72,538 8.16E-08 -0.93 0.19 
ATP1B1 rs6033 1 169,521,853 F5 exonic;nonsynonymous 0 0.066 92,046 1.59E-09 -0.94 0.16 
TTN-CCDC141 rs72648998 2 179,575,511 TTN exonic;nonsynonymous 0 0.053 92,046 1.91E-09 1.02 0.18 
TTN-CCDC141 rs34819099 2 179,628,918 TTN exonic;nonsynonymous 0 0.014 92,046 6.29E-08 1.81 0.34 
TTN-CCDC141 rs10497520 2 179,644,855 TTN exonic;nonsynonymous 1 0.185 89,173 1.28E-08 0.63 0.11 
SLC4A3 rs55910611 2 220,500,412 SLC4A3 exonic;nonsynonymous 0 0.006 70,928 6.02E-08 -3.24 0.62 
SCN5A-SCN10A rs116202356 3 38,103,776 DLEC1 exonic;nonsynonymous 0 0.015 92,046 2.49E-18 2.93 0.33 
SCN5A-SCN10A rs2070492 3 38,357,817 SLC22A14 exonic;nonsynonymous 0 0.096 92,046 4.26E-08 -0.67 0.14 
SCN5A-SCN10A rs2070488 3 38,442,490 XYLB intronic 0 0.518 92,046 4.38E-09 0.42 0.08 
SCN5A-SCN10A rs11129795 3 38,589,163 SCN5A downstream 0 0.233 92,046 3.66E-45 -1.30 0.10 
SCN5A-SCN10A rs12053903 3 38,593,393 SCN5A intronic 0 0.381 92,046 4.59E-47 -1.19 0.09 
SCN5A-SCN10A rs3922844 3 38,624,253 SCN5A intronic 0 0.336 89,173 4.19E-38 1.15 0.09 
SCN5A-SCN10A rs11708996 3 38,633,923 SCN5A intronic 0 0.135 86,309 6.14E-39 -1.55 0.12 
SCN5A-SCN10A rs1805124 3 38,645,420 SCN5A exonic;nonsynonymous 0 0.238 92,046 5.26E-25 0.97 0.10 
SCN5A-SCN10A rs11710077 3 38,657,899 SCN5A intronic 0 0.191 86,309 7.19E-31 1.19 0.11 
SCN5A-SCN10A rs9841329 3 38,687,803 SCN5A intronic 0 0.433 92,046 1.58E-09 -0.48 0.08 
SCN5A-SCN10A rs9851724 3 38,719,935  intergenic 0 0.306 76,918 2.96E-23 0.97 0.10 
SCN5A-SCN10A rs12632942 3 38,764,998 SCN10A exonic;nonsynonymous 0 0.245 92,046 1.37E-07 0.47 0.10 
SCN5A-SCN10A rs6795970 3 38,766,675 SCN10A exonic;nonsynonymous 0 0.364 92,046 1.06E-34 -0.99 0.09 
SCN5A-SCN10A rs57326399 3 38,768,300 SCN10A exonic;nonsynonymous 0 0.244 92,046 2.10E-10 0.59 0.10 
SCN5A-SCN10A rs6800541 3 38,774,832 SCN10A intronic 0 0.370 92,046 4.34E-33 -0.97 0.09 
CASR rs1801725 3 122,003,757 CASR exonic;nonsynonymous 0 0.125 92,046 2.38E-09 -0.65 0.12 
SENP2 rs6762208 3 185,331,165 SENP2 exonic;nonsynonymous 0 0.358 92,046 1.50E-07 0.44 0.08 
SLC4A4 rs7689609 4 72,083,374 SLC4A4 intronic 0 0.215 81,800 6.81E-08 0.64 0.12 
SLC12A7 rs737154 5 1,065,399 SLC12A7 exonic;splicing;synonymous 1 0.500 92,046 1.81E-07 -0.40 0.08 
CDKN1A rs1321311 6 36,622,900  intergenic 0 0.254 89,173 6.14E-14 -0.73 0.10 
CDKN1A rs9470361 6 36,623,379  intergenic 0 0.249 92,046 1.69E-15 -0.76 0.09 
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SLC35F1-PLN rs281868 6 118,574,061 SLC35F1 intronic 0 0.487 89,173 8.42E-15 0.59 0.08 
SLC35F1-PLN rs89107 6 118,578,043 SLC35F1 intronic 0 0.490 92,046 3.37E-39 1.03 0.08 
SLC35F1-PLN rs12210810 6 118,653,204  intergenic 0 0.046 86,309 2.81E-31 -2.16 0.20 
SLC35F1-PLN rs11153730 6 118,667,522  intergenic 0 0.467 92,046 4.33E-55 1.23 0.08 
SLC35F1-PLN rs11970286 6 118,680,374  intergenic 0 0.429 92,046 1.29E-44 1.12 0.08 
SLC35F1-PLN rs3734382 6 118,886,961 CEP85L exonic;nonsynonymous 0 0.257 92,046 1.72E-08 -0.50 0.09 
SLC35F1-PLN rs3734381 6 118,887,303 CEP85L exonic;nonsynonymous 0 0.461 88,035 3.22E-25 -0.84 0.08 
KCNH2 rs2968864 7 150,622,162  intergenic 0 0.215 89,173 3.67E-52 -1.51 0.10 
KCNH2 rs2968863 7 150,623,137  intergenic 0 0.215 89,173 1.97E-52 -1.52 0.10 
KCNH2 rs4725982 7 150,637,863  intergenic 0 0.223 92,046 8.11E-49 1.41 0.10 
KCNH2 rs1805123 7 150,645,534 KCNH2 exonic;nonsynonymous 0 0.214 92,046 1.06E-51 -1.49 0.10 
KCNH2 rs3807375 7 150,667,210 KCNH2 intronic 0 0.400 89,173 5.00E-37 1.10 0.09 
ZNF37A rs2474570 10 38,383,757 ZNF37A intronic 0 0.488 92,046 7.70E-09 -0.46 0.08 
ZNF37A rs4934956 10 38,814,815  intergenic 0 0.497 67,212 2.92E-08 0.53 0.10 
NRAP rs3189030 10 115,393,929 NRAP exonic;nonsynonymous 0 0.299 92,046 2.78E-08 -0.49 0.09 
NRAP rs2185913 10 115,410,234 NRAP exonic;nonsynonymous 1 0.270 92,046 6.14E-08 -0.51 0.09 
KCNQ1 rs800336 11 2,473,131 KCNQ1 intronic 0 0.314 89,173 1.19E-19 -0.84 0.10 
KCNQ1 rs2074238 11 2,484,803 KCNQ1 intronic 0 0.073 86,014 5.40E-135 -3.72 0.16 
KCNQ1 rs12296050 11 2,489,342 KCNQ1 intronic 0 0.230 92,046 1.62E-64 1.66 0.10 
KCNQ1 rs12576239 11 2,502,319 KCNQ1 intronic 0 0.139 92,046 1.96E-46 1.62 0.12 
KCNQ1 rs1080015 11 2,511,527 KCNQ1 intronic 0 0.397 92,046 3.66E-11 0.52 0.09 
KCNQ1 rs179429 11 2,550,730 KCNQ1 intronic 0 0.171 92,046 1.97E-08 -0.60 0.11 
KCNQ1 rs17215500 11 2,790,111 KCNQ1 exonic;stopgain 1 0.000 92,046 6.24E-12 46.25 5.60 
NACA rs2958149 12 57,109,792 NACA exonic;nonsynonymous 0 0.252 88,035 7.81E-08 0.53 0.10 
NACA rs2926743 12 57,114,100 NACA exonic;nonsynonymous 0 0.252 92,046 5.82E-08 0.53 0.09 
KLF12 rs1886512 13 74,520,186 KLF12 intronic 0 0.381 77,282 1.09E-15 0.71 0.09 
LITAF rs8049607 16 11,691,753  intergenic 0 0.502 92,046 5.10E-45 1.08 0.08 
MKL2 rs30208 16 14,428,853  intergenic 0 0.501 92,046 4.59E-09 0.44 0.08 
CNOT1 rs4356470 16 58,529,615 NDRG4 intronic 0 0.328 92,046 1.28E-19 -0.79 0.09 
CNOT1 rs7188697 16 58,622,178 CNOT1 intronic 0 0.247 88,035 4.65E-64 -1.60 0.10 
LIG3 rs2230553 17 33,269,648 CCT6B exonic;nonsynonymous 1 0.343 86,309 4.57E-09 -0.53 0.09 
LIG3 rs9635769 17 33,288,363 CCT6B exonic;nonsynonymous 0 0.452 92,046 2.02E-08 0.48 0.08 
LIG3 rs2074518 17 33,324,382 LIG3 intronic 0 0.428 89,173 6.60E-20 -0.78 0.08 
PRKCA rs56152251 17 64,280,153  intergenic 0 0.433 92,046 2.07E-17 -0.72 0.08 
PRKCA rs9912468 17 64,318,357 PRKCA intronic 0 0.416 86,309 7.15E-25 -0.87 0.09 
KCNJ2 rs17779747 17 68,494,992  intergenic 0 0.303 90,368 2.81E-35 -1.08 0.09 
Damaging: loss of function or predicted damaging by at least 2 of the following methods: Polyphen, LRT, 
SIFT, Mutation Taster (1=True, 0=False)[1]. CAF=coded allele frequency; N=sample size; BETA= effect size 
in milliseconds; SE=standard error of effect size estimate. Combined=all ethnicities meta-analysis; 
EA=European ancestry-only meta-analysis; AA=African American-only meta-analysis. 
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Supplemental Table 3: ExomeChip-wide Significant Variants in JT Meta-analysis -Continued- 
 EA  AA  QT Combined 
SNV CAF N P BETA SE  CAF N P BETA SE  P BETA SE 
rs709209 0.343 80,330 3.49E-55 1.40 0.09  0.708 9,584 7.43E-02 0.50 0.29  1.33E-48 1.23 0.09 
rs200882245 0.003 80,330 7.61E-09 -4.70 0.85  0.000 9,584 1.52E-01 12.17 9.57  2.70E-07 -4.16 0.85 
rs846111 0.272 61,143 9.74E-53 1.69 0.11  0.056 9,584 8.65E-01 0.43 0.57  1.51E-46 1.51 0.11 
rs627304 0.407 80,330 3.39E-07 -0.44 0.09  0.645 9,584 3.22E-01 -0.07 0.27  5.36E-06 -0.34 0.08 
rs3889814 0.130 77,457 2.21E-10 -0.78 0.13  0.760 9,584 8.50E-01 0.11 0.32  9.92E-06 -0.48 0.12 
rs1077514 0.139 77,457 1.39E-12 -0.86 0.13  0.487 9,584 4.31E-01 -0.17 0.26  4.08E-08 -0.58 0.11 
rs6676438 0.284 77,457 1.43E-40 1.25 0.10  0.858 9,584 1.94E-02 0.96 0.41  1.38E-37 1.15 0.09 
rs2880058 0.337 80,330 2.67E-191 2.65 0.09  0.718 9,584 3.57E-04 1.18 0.30  9.54E-177 2.41 0.09 
rs12143842 0.252 80,330 1.47E-275 3.49 0.10  0.123 9,584 5.08E-07 1.87 0.40  2.90E-255 3.18 0.10 
rs1415259 0.361 77,457 7.37E-164 2.43 0.09  0.614 9,584 2.64E-03 0.90 0.27  1.14E-145 2.15 0.08 
rs10494366 0.362 80,330 2.02E-167 2.42 0.09  0.614 9,584 2.98E-03 0.89 0.27  2.81E-149 2.15 0.08 
rs16857031 0.138 74,593 9.24E-73 2.25 0.13  0.291 9,584 3.44E-04 1.07 0.29  2.11E-66 1.94 0.12 
rs12029454 0.146 80,330 5.29E-139 2.99 0.12  0.285 9,584 4.79E-04 0.94 0.29  1.15E-123 2.53 0.11 
rs12725553 0.389 80,330 1.02E-60 1.45 0.09  0.586 9,584 2.85E-03 0.80 0.27  5.30E-59 1.34 0.08 
rs4657178 0.256 80,330 4.05E-106 2.14 0.10  0.359 9,584 4.44E-01 0.30 0.28  2.24E-92 1.84 0.09 
rs10919071 0.125 80,330 2.48E-30 -1.42 0.13  0.026 9,584 4.56E-01 -0.76 0.83  2.55E-30 -1.37 0.13 
rs6027 0.058 61,185 1.09E-11 -1.43 0.22  0.012 7,906 1.93E-01 -2.12 1.40  1.34E-10 -1.27 0.21 
rs6018 0.060 60,366 3.60E-11 -1.44 0.22  0.012 7,906 2.77E-01 -1.84 1.39  1.20E-09 -1.25 0.21 
rs6037 0.073 64,389 1.93E-08 -0.99 0.19  0.013 6,017 5.53E-01 -1.10 1.51  1.18E-06 -0.80 0.19 
rs6033 0.073 80,330 3.84E-10 -0.99 0.17  0.014 9,584 6.94E-01 -0.82 1.14  1.40E-08 -0.87 0.16 
rs72648998 0.058 80,330 1.25E-09 1.06 0.19  0.013 9,584 8.84E-01 0.19 1.16  3.20E-09 1.00 0.18 
rs34819099 0.016 80,330 2.20E-08 1.88 0.35  0.003 9,584 5.11E-01 -1.06 2.36  2.48E-07 1.72 0.34 
rs10497520 0.132 77,457 6.01E-08 0.66 0.13  0.528 9,584 2.51E-01 0.36 0.27  8.61E-09 0.63 0.11 
rs55910611 0.007 60,890 1.05E-07 -3.22 0.63  0.001 7,906 1.03E-01 -9.26 5.81  1.53E-07 -3.06 0.61 
rs116202356 0.017 80,330 6.23E-18 2.99 0.34  0.004 9,584 8.30E-02 2.42 2.09  3.08E-11 2.22 0.33 
rs2070492 0.098 80,330 1.87E-07 -0.67 0.15  0.075 9,584 1.47E-01 -0.58 0.51  9.31E-06 -0.51 0.14 
rs2070488 0.559 80,330 1.90E-10 0.49 0.09  0.216 9,584 2.73E-01 -0.56 0.32  2.76E-06 0.32 0.08 
rs11129795 0.242 80,330 2.33E-46 -1.39 0.10  0.181 9,584 9.74E-02 -0.37 0.34  1.07E-23 -0.93 0.10 
rs12053903 0.329 80,330 1.13E-49 -1.29 0.09  0.788 9,584 4.30E-01 -0.16 0.33  1.20E-26 -0.88 0.09 
rs3922844 0.308 77,457 1.03E-34 1.17 0.10  0.580 9,584 4.82E-06 1.33 0.27  1.75E-19 0.82 0.09 
rs11708996 0.149 74,593 1.89E-38 -1.58 0.13  0.041 9,584 4.31E-02 -1.23 0.67  7.31E-20 -1.08 0.12 
rs1805124 0.233 80,330 1.01E-22 0.98 0.10  0.286 9,584 1.49E-03 0.94 0.29  7.48E-12 0.66 0.10 
rs11710077 0.203 74,593 9.20E-28 1.16 0.11  0.105 9,584 6.08E-05 1.83 0.43  4.11E-14 0.78 0.11 
rs9841329 0.433 80,330 7.45E-09 -0.48 0.09  0.410 9,584 7.16E-02 -0.48 0.27  1.94E-04 -0.30 0.08 
rs9851724 0.326 66,880 3.69E-26 1.06 0.10  0.154 7,906 4.63E-01 0.50 0.42  1.58E-10 0.62 0.10 
rs12632942 0.258 80,330 8.58E-09 0.55 0.10  0.139 9,584 7.52E-01 -0.33 0.38  3.23E-04 0.33 0.09 
rs6795970 0.399 80,330 4.21E-33 -0.99 0.09  0.099 9,584 1.02E-03 -1.60 0.45  2.55E-17 -0.67 0.09 
rs57326399 0.260 80,330 1.18E-11 0.66 0.10  0.111 9,584 9.63E-01 -0.14 0.42  2.48E-05 0.41 0.09 
rs6800541 0.405 80,330 1.90E-31 -0.97 0.09  0.100 9,584 1.16E-03 -1.59 0.45  2.23E-16 -0.66 0.08 
rs1801725 0.136 80,330 2.16E-09 -0.66 0.13  0.036 9,584 7.64E-01 -0.29 0.71  4.30E-08 -0.58 0.12 
rs6762208 0.345 80,330 1.77E-10 0.55 0.09  0.477 9,584 2.03E-01 -0.26 0.26  1.76E-04 0.31 0.08 
rs7689609 0.140 71,762 2.09E-07 0.66 0.13  0.837 7,906 5.86E-03 1.17 0.45  3.88E-08 0.64 0.12 
rs737154 0.502 80,330 1.40E-06 -0.40 0.09  0.499 9,584 5.92E-02 -0.43 0.26  4.77E-06 -0.36 0.08 
rs1321311 0.239 77,457 2.13E-14 -0.79 0.10  0.383 9,584 1.06E-01 -0.55 0.27  1.12E-04 -0.39 0.09 
rs9470361 0.242 80,330 4.64E-15 -0.79 0.10  0.315 9,584 2.16E-02 -0.77 0.28  5.55E-05 -0.40 0.09 
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rs281868 0.497 77,457 5.35E-15 0.63 0.09  0.444 9,584 2.37E-01 0.21 0.26  1.92E-18 0.66 0.08 
rs89107 0.500 80,330 1.53E-41 1.13 0.09  0.446 9,584 2.28E-01 0.22 0.27  4.92E-53 1.19 0.08 
rs12210810 0.052 74,593 1.30E-32 -2.25 0.20  0.010 9,584 3.50E-01 -0.60 1.34  2.11E-35 -2.28 0.20 
rs11153730 0.494 80,330 4.72E-57 1.32 0.09  0.281 9,584 4.40E-02 0.59 0.29  4.88E-74 1.41 0.08 
rs11970286 0.458 80,330 1.12E-45 1.18 0.09  0.222 9,584 2.61E-02 0.77 0.32  7.86E-61 1.29 0.08 
rs3734382 0.251 80,330 3.46E-07 -0.48 0.10  0.249 9,584 1.03E-02 -0.73 0.30  3.97E-13 -0.63 0.09 
rs3734381 0.457 76,967 3.24E-26 -0.91 0.09  0.442 8,936 9.17E-02 -0.43 0.27  3.75E-36 -1.00 0.08 
rs2968864 0.239 77,457 4.32E-53 -1.55 0.10  0.046 9,584 8.66E-01 -0.26 0.64  5.13E-51 -1.48 0.10 
rs2968863 0.239 77,457 4.76E-53 -1.55 0.10  0.051 9,584 5.84E-01 -0.50 0.61  3.86E-51 -1.48 0.10 
rs4725982 0.213 80,330 9.09E-52 1.57 0.11  0.261 9,584 1.88E-01 0.27 0.30  1.16E-46 1.36 0.10 
rs1805123 0.236 80,330 7.69E-53 -1.53 0.10  0.046 9,584 9.73E-01 -0.14 0.64  6.67E-51 -1.47 0.10 
rs3807375 0.357 77,457 5.23E-42 1.24 0.09  0.697 9,584 5.87E-01 -0.18 0.29  6.66E-37 1.08 0.08 
rs2474570 0.484 80,330 3.81E-09 -0.50 0.09  0.506 9,584 6.70E-01 -0.15 0.26  8.85E-10 -0.48 0.08 
rs4934956 0.497 57,822 4.10E-09 0.61 0.11  0.512 7,258 9.96E-01 -0.02 0.31  2.29E-10 0.58 0.10 
rs3189030 0.316 80,330 5.40E-08 -0.51 0.09  0.143 9,584 1.40E-01 -0.54 0.37  3.77E-08 -0.48 0.09 
rs2185913 0.296 80,330 2.71E-08 -0.53 0.09  0.059 9,584 9.41E-01 -0.10 0.57  1.92E-07 -0.48 0.09 
rs800336 0.247 77,457 3.68E-21 -0.91 0.10  0.827 9,584 4.91E-01 -0.41 0.35  5.94E-17 -0.77 0.10 
rs2074238 0.082 74,298 2.93E-133 -3.78 0.16  0.018 9,584 2.78E-03 -2.11 1.01  8.22E-130 -3.58 0.16 
rs12296050 0.191 80,330 3.99E-72 1.91 0.11  0.522 9,584 6.71E-02 0.53 0.26  8.87E-58 1.57 0.10 
rs12576239 0.135 80,330 7.71E-57 1.94 0.13  0.177 9,584 5.90E-01 -0.27 0.34  2.10E-40 1.51 0.12 
rs1080015 0.362 80,330 1.82E-13 0.63 0.09  0.675 9,584 4.12E-01 -0.34 0.28  1.68E-09 0.48 0.08 
rs179429 0.170 80,330 9.96E-08 -0.59 0.12  0.196 9,584 2.24E-01 -0.54 0.33  3.51E-08 -0.59 0.11 
rs17215500 0.000 80,330 3.66E-09 42.79 6.19  0.000 9,584 2.71E-04 61.97 13.18  1.11E-11 46.38 5.71 
rs2958149 0.270 76,967 3.39E-08 0.56 0.10  0.102 8,936 2.75E-01 0.41 0.45  2.57E-04 0.37 0.10 
rs2926743 0.271 80,330 2.14E-08 0.56 0.10  0.103 9,584 3.05E-01 0.40 0.44  2.68E-04 0.36 0.09 
rs1886512 0.370 65,566 1.85E-16 0.77 0.10  0.471 9,584 3.20E-01 0.34 0.26  1.53E-10 0.57 0.09 
rs8049607 0.508 80,330 1.90E-42 1.13 0.09  0.454 9,584 3.25E-04 0.75 0.26  8.42E-44 1.05 0.08 
rs30208 0.510 80,330 1.23E-10 0.51 0.09  0.432 9,584 9.77E-01 0.00 0.27  2.28E-09 0.45 0.08 
rs4356470 0.307 80,330 1.22E-21 -0.90 0.09  0.448 9,584 4.19E-01 -0.16 0.27  1.37E-20 -0.80 0.09 
rs7188697 0.254 76,967 3.38E-66 -1.70 0.10  0.153 8,936 1.97E-02 -0.92 0.37  3.78E-63 -1.57 0.10 
rs2230553 0.369 74,593 8.86E-09 -0.54 0.09  0.170 9,584 1.86E-01 -0.50 0.35  1.65E-10 -0.56 0.09 
rs9635769 0.425 80,330 1.26E-08 0.51 0.09  0.687 9,584 7.96E-01 0.05 0.29  2.77E-08 0.47 0.08 
rs2074518 0.461 77,457 9.48E-19 -0.77 0.09  0.177 9,584 1.81E-02 -0.88 0.35  2.16E-21 -0.79 0.08 
rs56152251 0.421 80,330 3.43E-15 -0.71 0.09  0.526 9,584 2.47E-03 -0.84 0.26  4.89E-11 -0.57 0.08 
rs9912468 0.420 74,593 4.07E-20 -0.84 0.09  0.379 9,584 1.23E-06 -1.24 0.27  1.54E-15 -0.68 0.08 
rs17779747 0.327 80,330 3.50E-36 -1.11 0.09  0.091 7,906 5.01E-02 -1.06 0.54  3.34E-37 -1.08 0.09 
Damaging: loss of function or predicted damaging by at least 2 of the following methods: Polyphen, LRT, 
SIFT, Mutation Taster (1=True, 0=False)[1]. CAF=coded allele frequency; N=sample size; BETA= effect size 
in milliseconds; SE=standard error of effect size estimate. Combined=all ethnicities meta-analysis; 
EA=European ancestry-only meta-analysis; AA=African American-only meta-analysis. 
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Supplemental Table 4: GWiS Results 
Locus Name Gene SNV Chr Position 
SNPs 
Tested # Tests N r2 SNV P  Function 
LD w/ 
QTIGC 
RNF207 RNF207 rs709209 1 6,278,414 191 175.551 83,884 0.000 1E-50 Nonsynonymous 0.696 
 RNF207 rs200882245 1 6,279,316 191 175.551 83,884 0.001 1E-07 Nonsynonymous 0.001 
TCEA3 ASAP3 rs1077514 1 23,766,233 241 208.235 81,011 0.000 3E-09 Intronic 0.060 
NOS1AP  rs12143842 1 162,033,890 214 195.062 83,884 0.000 2E-258 Intergenic 0.989 
 NOS1AP rs4657178 1 162,210,610 214 195.062 83,884 0.055 2E-104 Intronic 0.053 
 NOS1AP rs16857031 1 162,112,910 214 195.062 77,837 0.067 2E-70 Intronic 0.047 
ATP1B1 ATP1B1 rs10919071 1 169,099,483 182 160.218 83,884 0.000 5E-32 Intronic 0.964 
PM20D1 PM20D1 rs1361754 1 205,801,872 228 206.79 83,884 0.000 4E-10 Nonsynonymous QT Novel 
SLC8A1  None 2 39,959,060 26 25.3846      
SP3 SP3 rs1047640 2 174,820,750 79 77.9712 83,884 0.000 2E-06 Nonsynonymous 0.218 
TTN-CCDC141 TTN rs72648998 2 179,575,511 651 482.158 83,884 0.000 3E-09 Nonsynonymous 0.044 
 TTN rs72646869 2 179,446,381 651 482.158 83,884 0.002 7E-07 Nonsynonymous 0.017 
 TTN rs16866378 2 179,393,111 651 482.158 83,884 0.001 8E-07 Nonsynonymous 0.009 
SPATS2L  None 2 201,303,848 140 129.204      
SLC4A3 SLC4A3 rs55910611 2 220,500,412 500 436.507 64,444 0.000 2E-07 Nonsynonymous QT Novel 
 STK11IP rs620698 2 220,466,199 500 436.507 81,011 0.000 9E-07 Intronic QT Novel 
SCN5A-
SCN10A SCN5A rs12053903 3 38,593,393 413 365.284 83,884 0.000 9E-28 Intronic 0.970 
 SCN5A rs3922844 3 38,624,253 413 365.284 81,011 0.002 3E-18 Intronic 0.002 
 SCN10A rs6795970 3 38,766,675 413 365.284 83,884 0.001 2E-16 Nonsynonymous 0.001 
  rs9851724 3 38,719,935 413 365.284 70,434 0.010 9E-12 Intergenic 0.000 
C3ORF75  None 3 47,282,303 327 279.961      
CASR CASR rs1801725 3 122,003,757 322 275.414 83,884 0.000 5E-08 Nonsynonymous QT Novel 
SENP2 SENP2 rs6762208 3 185,331,165 156 142.145 80,330 0.000 2E-10 Nonsynonymous JT Novel 
SLC4A4 SLC4A4 rs7689609 4 72,083,374 160 148.664 75,316 0.000 6E-08 Intronic 0.673 
SMARCAD1 SMARCAD1 rs7439869 4 95,173,779 52 45.2488 83,884 0.000 1E-06 Nonsynonymous 0.539 
SLC12A7 SLC12A7 rs737154 5 1,065,399 272 245.212 80,330 0.000 1E-06 
Splicing/Synony
mous JT Novel 
GFRA3  None 5 137,441,767 136 124.32      
GMPR GMPR rs1042391 6 16,290,761 61 57.9877 77,837 0.000 1E-06 Nonsynonymous 0.989 
CDKN1A  rs9470361 6 36,623,379 223 207.828 80,330 0.000 5E-15 Intergenic JT Novel 
SLC35F1-PLN  rs11153730 6 118,667,522 104 95.8603 83,884 0.000 1E-76 Intergenic 0.988 
  rs12210810 6 118,653,204 104 95.8603 77,837 0.055 2E-36 Intergenic 0.050 
CAV1 CAV1 rs3807989 7 116,186,241 93 87.7895 83,884 0.000 4E-10 Intronic 0.168 
KCNH2 KCNH2 rs1805123 7 150,645,534 316 285.068 83,884 0.000 7E-52 Nonsynonymous 0.823 
  rs4725982 7 150,637,863 316 285.068 83,884 0.087 2E-48 Intergenic 0.088 
NCOA2  None 8 71,164,680 91 87.976      
LAPTM4B  None 8 99,045,866 117 112.946      
AZIN1  None 8 104,432,659 81 75.9971      
ZNF37A  rs4934956 10 38,814,815 30 26.7679 61,376 0.000 3E-11 Intergenic QT Novel 
GBF1  None 10 104,174,986 187 167.445      
NRAP NRAP rs3189030 10 115,393,929 232 204.795 83,884 0.000 7E-08 Nonsynonymous QT Novel 
KCNQ1 KCNQ1 rs2074238 11 2,484,803 210 197.041 77,542 0.000 3E-127 Intronic 0.021 
 KCNQ1 rs12296050 11 2,489,342 210 197.041 83,884 0.018 8E-64 Intronic 0.992 
 KCNQ1 rs17215500 11 2,790,111 210 197.041 83,884 0.000 5E-09 Stop 0.000 
 KCNQ1 rs800336 11 2,473,131 210 197.041 81,011 0.018 4E-18 Intronic 0.000 
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FEN1-FADS2 FADS2 rs1535 11 61,597,972 439 394.132 83,884 0.000 5E-10 Intronic 0.952 
NACA NACA rs2926743 12 57,114,100 554 482.888 80,330 0.000 2E-08 Nonsynonymous JT Novel 
ATP2A2 GIT2 rs11068997 12 110,383,141 182 166.358 83,884 0.000 6E-07 Nonsynonymous 0.018 
 TCTN1 rs75714509 12 111,080,097 182 166.358 83,884 0.000 2E-06 Nonsynonymous 0.018 
KLF12 KLF12 rs1886512 13 74,520,186 25 23.8208 68,810 0.000 8E-11 Intronic 0.955 
ANKRD9  None 14 102,808,655 154 136.308      
USP50-TRPM7  None 15 50,878,630 177 165.088      
CREBBP  None 16 3,336,067 507 450.414      
LITAF  rs8049607 16 11,691,753 173 159.823 83,884 0.000 1E-41 Intergenic 0.736 
MKL2  rs30208 16 14,428,853 63 60.4452 83,884 0.000 2E-11 Intergenic 0.342 
CNOT1 CNOT1 rs7188697 16 58,622,178 196 184.334 80,521 0.000 8E-65 Intronic 0.984 
LIG3 LIG3 rs2074518 17 33,324,382 281 254.997 81,011 0.000 4E-20 Intronic 0.994 
GOSR2 GOSR2 rs17608766 17 45,013,271 117 108.077 83,884 0.000 5E-09 UTR3 QT Novel 
PRKCA PRKCA rs9912468 17 64,318,357 95 88.6125 77,837 0.000 3E-12 Intronic 0.993 
KCNJ2  rs17779747 17 68,494,992 27 26.8937 83,884 0.000 2E-37 Intergenic 0.388 
KCNE1  None 21 35,880,072 129 118.746      
GWiS was run on all variants in each locus (most significant SNP ±1 MB) from the European ancestry-only QT 
or JT interval association. SNVs are added into the GWiS model in the order they are listed. r2= r2 between the 
SNV being added to the model and the previous SNV held in the model (or zero for the first SNV); # Tests= 
number of independent tests after accounting for LD between SNVs. For the 35 previously identified loci, LD 
calculations are shown in Supplemental Table 3 between the QTIGC representative SNV and each of the 
independent representative SNVs picked by GWiS. LD calculations are performed in the merged ExomeChip 
and HapMap-imputed ARIC Europeans dataset with 9,537 samples. LD is made bold if >0.5. Loci with no 
SNPs are those in which no SNPs were significant after multi-test correction. 
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Supplemental Table 5: Multi-SNV Analysis of the SCN5A-SCN10A Locus 
 
Supplemental Table 5A: Significant Coding Variants 
Gene SNV Chr 
Coded/ 
Noncoded 
Allele CAF 
Effect 
in ms P Function 
DLEC1 rs116202356 3 G/A 0.02 2.22 3E-11 Nonsynonymous 
SCN5A rs1805124 3 T/C 0.24 0.66 7E-12 Nonsynonymous 
SCN10A rs6795970 3 A/G 0.37 -0.67 3E-17 Nonsynonymous 
Supplemental Table tB: GWiS Results 
Nearby 
Gene SNV Chr 
SNVs 
Tested # Tests r2 P Function 
SCN5A rs12053903 3 413 365.3 0.000 9E-28 Intronic 
SCN5A rs3922844 3 413 365.3 0.002 3E-18 Intronic 
SCN10A rs6795970 3 413 365.3 0.001 2E-16 Nonsynonymous 
 rs9851724 3 413 365.3 0.010 9E-12 Intergenic 
 
Supplemental Table 5A lists the 3 ExomeChip-wide significant coding variants in the SCN5A-SCN10A locus 
from the all ancestries QT association. Supplemental Table 5B contains the result of running GWiS on all 413 
variants in the locus from the European ancestry-only QT association. 4 variants representing 4 independent 
effects in the locus are shown with one of them being represented by a coding variant in SCN10A. “r2” is the 
correlation between the SNV being added to the model and the previous SNV held in the model (or zero for the 
first SNV). “# Tests” is the effective number of independent tests in the locus, which is fewer than “SNPs 
Tested” due to LD between SNVs. Supplemental Table 5A uses data from 95,626 multi-ethnic individuals. 
Supplemental Table 5B uses data from 83,884 European ancestry individuals. 
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Supplemental Table 6: Conditional Analyses in ARIC European Ancestry Individuals for ExomeChip SNVs and QTIGC SNPs 
 
Conditional analyses demonstrate that the coding variant in SP3 is independent of the top noncoding SNV at this locus discovered from QT-IGC, 
implicating this gene in QT interval modulation. For GMPR, the coding variant is in almost perfect linkage disequilibrium with the noncoding QT-
IGC variant (r2=0.99 in ARIC), suggesting that the coding variant may be the causal variant explaining the QT-IGC signal. For a third locus, 
RNF207, while conditional analysis suggested that the QT-IGC SNV accounts for the association at this locus, both the top QT-IGC SNV as well as 
the top SNV from this study are coding variants in high LD, thus implicating the RNF207 gene in myocardial repolarization. For the remaining 4 
loci, one coding variant is associated due to the stronger noncoding QT-IGC signal (KCNH2); two were not properly tested due to no effect in ARIC 
of the ExomeChip variant (ATP2A2) or the QT-IGC variant (TTN), though there was low LD (r2<0.04) between the coding and non-coding variants, 
suggesting independence; and 1 was unclear (SMARCAD1), as putting both SNPs in the model significantly altered the beta estimates for both SNPs. 
 EA Meta-analysis ARIC  ARIC Conditional Analyses   
Locus 
Name EC SNV 
EC 
CAF 
EC 
Beta 
QTIGC 
SNV 
QTIGC 
CAF 
QTIGC 
Beta 
EC 
Beta EC P 
QTIGC 
Beta QTIGC P LD  
EC 
Beta EC P 
QTIGC 
Beta QTIGC P Con Survive Notes 
RNF207 rs709209 0.38 1.23 rs846111 0.28 1.73 1.11 1.65E-06 1.38 3.49E-08 0.70 0.16 6.92E-01 1.23 5.91E-03 QTIGC 
QTIGC signal (also a 
coding SNV) explains 
ExomeChip signal 
SP3 rs1047640 0.12 0.60 rs938291 0.39 0.53 1.11 7.61E-04 0.77 6.41E-04 0.22 0.75 4.37E-02 0.52 3.95E-02 Both The two signals are independent 
TTN-
CCDC141 rs72648998 0.05 1.00 rs7561149 0.42 -0.52 1.29 4.72E-03 -0.12 5.76E-01 0.04 1.30 5.50E-03 0.01 9.65E-01 Inconclusive 
QTIGC signal not present 
in ARIC before the 
conditional analysis 
SMARCAD1 rs7439869 0.38 0.41 rs3857067 0.46 -0.51 0.63 4.30E-03 -0.65 3.13E-03 0.54 0.33 3.12E-01 -0.41 2.06E-01 Inconclusive 
Variants may tag the 
same haplotype, 
possibly a third variant is 
causal 
GMPR rs1042391 0.55 -0.42 rs7765828 0.40 0.55 -0.50 2.33E-02 0.52 1.84E-02 0.99     Inconclusive Variants are equivalent due to high LD 
KCNH2 rs1805123 0.21 -1.47 rs2072413 0.27 -1.68 -1.32 2.51E-07 -1.43 6.39E-09 0.82 0.17 7.82E-01 -1.58 7.27E-03 QTIGC 
QTIGC intronic signal 
explains ExomeChip 
signal 
ATP2A2 rs11068997 0.04 -0.94 rs3026445 0.36 0.62 -0.07 9.05E-01 0.46 4.57E-02 0.02 0.11 8.67E-01 0.46 4.54E-02 Inconclusive 
ExomeChip signal not 
present in ARIC before 
the conditional analysis 
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EC=ExomeChip (this study); The “Con Survive” column indicates if the ExomeChip SNV or QTIGC SNP or both have effect size estimates that 
remain unchanged in the conditional model. LD calculations are performed in the merged ExomeChip and HapMap-imputed most likely genotype 
ARIC Europeans dataset with 9,537 samples. Conditional analyses were run in the same ARIC Europeans dataset, however limited to 9,005 
individuals due to phenotype exclusions. Effect sizes (Beta) are in milliseconds. 
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Supplemental Table 7: DEPICT Loci Description 
SNV Chr Locus Start Locus Stop Nearest Genes Genes in Locus 
rs1042391 6 16,205,060 16,295,589 ENSG00000137198 ENSG00000137198 
rs1047640 2 174,739,352 174,820,900 ENSG00000172845 ENSG00000172845 
rs1077514 1 23,735,241 23,823,798 ENSG00000088280 ENSG00000088280;ENSG00000204219 
rs10919071 1 169,088,679 169,429,035 ENSG00000143153 ENSG00000143153;ENSG00000143156 
rs11068997 12 110,298,498 111,171,342 ENSG00000139437;ENSG00000139436 ENSG00000122970;ENSG00000122986 
rs11153730 6 118,561,348 119,027,325 ENSG00000196376 ENSG00000198523;ENSG00000196376 
rs11704 14 102,808,330 102,974,999 ENSG00000022976 ENSG00000156381;ENSG00000022976 
rs12053903 3 38,575,865 38,601,556 ENSG00000183873 ENSG00000157036;ENSG00000183873 
rs12143842 1 162,014,632 162,053,060 ENSG00000198929 ENSG00000198929 
rs1361754 1 205,676,088 205,809,642 ENSG00000162877 ENSG00000117280;ENSG00000069275 
rs1535 11 61,543,499 61,623,140 ENSG00000149485;ENSG00000134824 ENSG00000168496;ENSG00000149485 
rs17608766 17 45,013,238 45,054,564 ENSG00000108433 ENSG00000108433 
rs17779747 17 68,411,445 68,515,552 ENSG00000123700  
rs17831160 8 98,994,459 99,046,298 ENSG00000156482;ENSG00000132561 ENSG00000156482;ENSG00000132561 
rs1801725 3 121,993,247 122,130,141 ENSG00000036828 ENSG00000036828;ENSG00000114023 
rs1805123 7 150,600,845 150,657,209 ENSG00000055118 ENSG00000055118 
rs1886512 13 74,511,991 74,558,505 ENSG00000118922 ENSG00000118922 
rs2074238 11 2,482,918 2,485,092 ENSG00000053918 ENSG00000053918 
rs2074518 17 33,313,729 33,440,166 ENSG00000005156 ENSG00000092871;ENSG00000005156 
rs2276853 3 46,982,737 47,583,156 ENSG00000227398;ENSG00000088727 ENSG00000227398;ENSG00000181555 
rs2540226 2 39,884,712 40,062,975 ENSG00000138050 ENSG00000152154;ENSG00000138050 
rs2926707 8 71,042,430 71,340,989 ENSG00000140396 ENSG00000213003;ENSG00000140396 
rs2926743 12 56,983,252 57,212,827 ENSG00000196531 ENSG00000198056;ENSG00000076067 
rs30208 16 14,405,892 14,440,874 ENSG00000186260  
rs3189030 10 115,350,100 115,484,660 ENSG00000197893 ENSG00000165806;ENSG00000197893 
rs3807989 7 116,073,567 116,225,704 ENSG00000105974 ENSG00000105971;ENSG00000105974 
rs4835768 5 137,179,924 137,544,397 ENSG00000112981 ENSG00000120729;ENSG00000031003 
rs6762208 3 185,289,989 185,353,235 ENSG00000163904 ENSG00000163904 
rs709209 1 6,272,137 6,305,053 ENSG00000158286 ENSG00000225077;ENSG00000116237 
rs7188697 16 58,543,746 58,668,652 ENSG00000125107 ENSG00000103037;ENSG00000103034 
rs727957 21 35,853,176 35,883,030 ENSG00000180509 ENSG00000180509 
rs737154 5 1,028,876 1,094,389 ENSG00000113504 ENSG00000113504;ENSG00000145506 
rs7439869 4 95,012,684 95,334,650 ENSG00000163104 ENSG00000163106;ENSG00000163104 
rs7689609 4 72,083,058 72,299,192 ENSG00000080493 ENSG00000080493 
rs8042919 15 50,847,978 51,103,393 ENSG00000092439 ENSG00000092439;ENSG00000138600 
rs8049607 16 11,689,015 11,693,536 ENSG00000189067  
rs9470361 6 36,613,812 36,647,289 ENSG00000164530 ENSG00000164530;ENSG00000124762 
rs9912468 17 64,197,259 64,331,037 ENSG00000154229 ENSG00000154229;ENSG00000091583 
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Supplemental Figure 1: Manhattan Plot of QT Associated Hits. Significance level (-log10(P)) for each tested variant from single variant statistical 
models is plotted by genomic location. Loci of interest are labeled by nearby gene. Figure truncated at -log10(P)=24. 
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Supplemental Figure 2: Correlation of Effect Estimates between Ethnic Groups. Correlation of effect estimates (Beta) between European 
Ancestry (EA) individuals and African American (AA) individuals (left panel) Hispanic (HIS) individuals (center panel) and Chinese (CHS) 
individuals (right panel). Effect estimates are in milliseconds. The line is the 45 degree identity line. 
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Supplemental Figure 3: Manhattan plot of JT-only Associated Hits. Significance level (-log10(P)) for each tested variant from single variant 
statistical models is plotted by genomic location. Loci of interest are labeled by nearby gene. Figure truncated at -log10(P)=24. Only non-QT 
associated loci labeled. 
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Supplemental Figure 4: Forest Plot of rs1361754 Association with QT interval.
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Supplemental Figure 5: Forest Plot of rs1801725 Association with QT interval. 
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Supplemental Figure 6: Forest Plot of rs3189030 Association with QT interval. 
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Supplemental Figure 7: Forest Plot of rs4934956 Association with QT interval. 
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Supplemental Figure 8: Forest Plot of rs17608766 Association with QT interval. 
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Supplemental Figure 9: Forest Plot of rs55910611 Association with QT interval. 
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Supplemental Figure 10: Forest Plot of rs737154 Association with JT interval. 
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Supplemental Figure 11: Forest Plot of rs2926743 Association with JT interval. 
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Supplemental Figure 12: Forest Plot of rs6762208 Association with JT interval. 
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Supplemental Figure 13: Forest Plot of rs9470361 Association with JT interval. 
 
 
This is an overview of an article entitled “ExomeChip-Wide Analysis of 95,626 
Individuals Identifies 10 Novel Loci Associated with QT and JT Intervals”, published 
in the January 2018 issue of Circulation: Genomic and Precision Medicine. 
 
The electrocardiographic QT interval spans from the beginning of the QRS complex 
to the end of the T wave, as shown in the schematic here. The QT interval is 
measured in order to assess the length of duration of ventricular repolarization. 
Abnormality of the QT interval in either direction, too long or too short, predisposes 
to arrhythmias and sudden cardiac death. The JT interval, as shown here, is a more 
precise measure of ventricular repolarization since it subtracts the QRS interval, 
which is when ventricular depolarization occurs, from the QT interval. 
 
To assess for genetic factors that contribute to clinical traits, genetic association 
studies are performed. The most commonly done association study has been the 
genome-wide association study, or GWAS, which assesses common DNA variants 
throughout the genome for strength of association with the phenotype of interest. 
These common variants are for the most part noncoding variants. More recently, 
exome chips that can directly interrogate coding variants in genes have become 
available. While the exome chips do cover some noncoding variants, they are very 
comprehensive with respect to coding variants, covering all coding variants that 
were found in at least 3 individuals out of 12,000 individuals who had undergone 
exome sequencing. This comprises almost 200,000 coding variants in more than 
17,000 genes. 
 
The authors of the paper under discussion performed an exome chip genotyping 
association study in more than 95,000 individuals, most of whom were of European 
descent, although several other ethnicities were represented in smaller numbers. 
The rationale for using the exome chip is that GWASs tend to identify noncoding 
variants that often do not pinpoint specific genes, since noncoding variants can 
affect genes at a large distance, meaning that each GWAS hit might implicate 
numerous candidate genes in the vicinity of the locus. In contrast, exome chip 
studies tend to identify coding variants within genes, which implicate those specific 
genes as the causal genes. 
 
Here are the results of the exome chip analysis with the QT interval. In this graph, 
the x-axis is the position in the genome, split into different chromosomes, and the y-
axis is the strength of association. The green line indicates a stringent threshold for 
statistical significance, taking into account the hundreds of thousands of variants 
tested in the study. Many known loci implicated by previous association studies 
were validated in this study, indicated in yellow. In red are genes or loci being linked 
to the QT interval for the first time in this study. 
 
Here are the genes or loci associated with the JT interval but not the QT interval. 
There were no prior loci linked only to the JT interval. This study found 4 novel 
genes or loci, indicated in red. 
 
There were several key findings in this study. First, the exome chip analysis 
identified coding variants in two notable genes as being linked to the QT interval, 
SCN10A and KCNQ1. Both have previously been linked to cardiac repolarization—
SCN10A to Brugada syndrome by GWAS, and KCNQ1 is the well-established causal 
gene for long QT syndrome type 1. [pause] Second, the study found 4 hits associated 
only with the JT interval. Third, functional annotation of the various exome chip hits 
identified several known pathways—potassium, sodium, or calcium ion regulation, 
and autonomic control—and new pathways—the physical force of contraction of 
cardiomyocytes, as well as conduction of the electrical signal between 
cardiomyocytes. 
 
In conclusion, this study identified a total of 10 new loci associated with the QT 
and/or JT interval. The exome chip analysis pinpointed variants in 17 genes, 7 of 
which are in new loci. These findings validated previously identified molecular 
pathways involved in cardiac repolarization and nominated new pathways. Finally, 
by identifying hits linked to the JT interval but not the QT interval, this study 
suggests that different genetic factors might influence the depolarization and 
repolarization phases of the ventricles. Together, these findings shed new light on 
normal cardiac electrophysiology, diseases with repolarization abnormalities, and 
potential treatments for the diseases. 
 
